ALIGN TECHNOLOGY INC
10-Ks and 10-Qs
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________________
FORM 10-Q
____________________________
(Mark One)
|
x
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
For the quarterly period ended
March 31, 2013
OR
|
¨
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
For the transition period from to
Commission file number: 0-32259
____________________________
ALIGN TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
____________________________
|
Delaware
|
94-3267295
|
|
(State or other jurisdiction of
incorporation or organization)
|
(I.R.S. Employer
Identification Number)
|
2560 Orchard Parkway
San Jose, California 95131
(Address of principal executive offices)
(408) 470-1000
(Registrant’s telephone number, including area code)
____________________________
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes
x
No
¨
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes
x
No
¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
|
Large accelerated filer
|
x
|
Accelerated filer
|
¨
|
|
Non-accelerated filer
|
o
(Do not check if a smaller reporting company)
|
Smaller reporting company
|
¨
|
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes
¨
No
x
The number of shares outstanding of the registrant’s Common Stock, $0.0001 par value, as of April 26, 2013
was
81,557,143
ALIGN TECHNOLOGY, INC.
INDEX
|
PART I
|
||
|
ITEM 1.
|
||
|
ITEM 2.
|
||
|
ITEM 3.
|
||
|
ITEM 4.
|
||
|
PART II
|
||
|
ITEM 1.
|
||
|
ITEM 1A.
|
||
|
ITEM 2.
|
||
|
ITEM 3.
|
||
|
ITEM 4.
|
||
|
ITEM 5.
|
||
|
ITEM 6.
|
||
Invisalign, Align, ClinCheck, Invisalign Assist, Invisalign Teen Vivera, SmartForce, SmartTrack, Power Ridges, iTero, Orthocad iCast and Orthocad iRecord amongst others, are trademarks belonging to Align Technology, Inc., and/or its subsidiaries and are pending or registered in the United States and other countries.
2
ALIGN TECHNOLOGY, INC.
(in thousands, except per share data)
(unaudited)
|
Three Months Ended
|
|||||||
|
|
March 31,
|
||||||
|
|
2013
|
2012
|
|||||
|
Net revenues
|
$
|
153,580
|
|
$
|
135,079
|
|
|
|
Cost of net revenues
|
40,731
|
|
34,319
|
|
|||
|
Gross profit
|
112,849
|
|
100,760
|
|
|||
|
Operating expenses:
|
|||||||
|
Sales and marketing
|
42,281
|
|
38,717
|
|
|||
|
General and administrative
|
30,348
|
|
23,511
|
|
|||
|
Research and development
|
11,282
|
|
10,526
|
|
|||
|
Impairment of goodwill
|
40,693
|
|
—
|
|
|||
|
Impairment of long-lived assets
|
26,320
|
|
—
|
|
|||
|
Total operating expenses
|
150,924
|
|
72,754
|
|
|||
|
Income (loss) from operations
|
(38,075
|
)
|
28,006
|
|
|||
|
Other expenses, net
|
(988
|
)
|
(812
|
)
|
|||
|
Net income (loss) before provision for income taxes
|
(39,063
|
)
|
27,194
|
|
|||
|
Provision for income taxes
|
2,920
|
|
6,210
|
|
|||
|
Net income (loss)
|
$
|
(41,983
|
)
|
$
|
20,984
|
|
|
|
Net income (loss) per share:
|
|||||||
|
Basic
|
$
|
(0.52
|
)
|
$
|
0.26
|
|
|
|
Diluted
|
$
|
(0.52
|
)
|
$
|
0.26
|
|
|
|
Shares used in computing net income (loss) per share:
|
|||||||
|
Basic
|
81,248
|
|
79,235
|
|
|||
|
Diluted
|
81,248
|
|
81,856
|
|
|||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
3
ALIGN TECHNOLOGY, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(in thousands)
(unaudited)
|
Three Months Ended
|
|||||||
|
|
March 31,
|
||||||
|
|
2013
|
2012
|
|||||
|
Net income (loss)
|
$
|
(41,983
|
)
|
$
|
20,984
|
|
|
|
Net change in cumulative translation adjustment
|
(55
|
)
|
159
|
|
|||
|
Change in unrealized gains (losses) on available-for-sale securities, net of tax
|
3
|
|
(12
|
)
|
|||
|
Other comprehensive income (loss)
|
(52
|
)
|
147
|
|
|||
|
Comprehensive income (loss)
|
$
|
(42,035
|
)
|
$
|
21,131
|
|
|
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
4
ALIGN TECHNOLOGY, INC.
(in thousands, except per share data)
(unaudited)
|
March 31,
2013 |
December 31,
2012 |
||||||
|
ASSETS
|
|||||||
|
Current assets:
|
|||||||
|
Cash and cash equivalents
|
$
|
328,745
|
|
$
|
306,386
|
|
|
|
Restricted cash
|
508
|
|
1,575
|
|
|||
|
Marketable securities, short-term
|
37,975
|
|
28,485
|
|
|||
|
Accounts receivable, net of allowance for doubtful accounts and returns of $1,247 and $2,484, respectively
|
108,672
|
|
98,992
|
|
|||
|
Inventories
|
15,442
|
|
15,122
|
|
|||
|
Prepaid expenses and other current assets
|
35,989
|
|
35,233
|
|
|||
|
Total current assets
|
527,331
|
|
485,793
|
|
|||
|
Marketable securities, long-term
|
10,680
|
|
21,252
|
|
|||
|
Property, plant and equipment, net
|
72,672
|
|
79,191
|
|
|||
|
Goodwill
|
58,543
|
|
99,236
|
|
|||
|
Intangible assets, net
|
25,429
|
|
45,777
|
|
|||
|
Deferred tax assets
|
28,417
|
|
21,609
|
|
|||
|
Other assets
|
3,173
|
|
3,454
|
|
|||
|
Total assets
|
$
|
726,245
|
|
$
|
756,312
|
|
|
|
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
|||||||
|
Current liabilities:
|
|||||||
|
Accounts payable
|
$
|
19,748
|
|
$
|
19,549
|
|
|
|
Accrued liabilities
|
64,635
|
|
74,247
|
|
|||
|
Deferred revenues
|
59,472
|
|
61,975
|
|
|||
|
Total current liabilities
|
143,855
|
|
155,771
|
|
|||
|
Other long-term liabilities
|
21,272
|
|
19,224
|
|
|||
|
Total liabilities
|
165,127
|
|
174,995
|
|
|||
|
Commitments and contingencies (Note 7)
|
|
|
|||||
|
Stockholders’ equity:
|
|||||||
|
Preferred stock, $0.0001 par value (5,000 shares authorized; none issued)
|
—
|
|
—
|
|
|||
|
Common stock, $0.0001 par value (200,000 shares authorized; 81,725 and 80,611 issued and outstanding in 2013 and 2012, respectively)
|
8
|
|
8
|
|
|||
|
Additional paid-in capital
|
694,334
|
|
670,732
|
|
|||
|
Accumulated other comprehensive income, net
|
151
|
|
203
|
|
|||
|
Accumulated deficit
|
(133,375
|
)
|
(89,626
|
)
|
|||
|
Total stockholders’ equity
|
561,118
|
|
581,317
|
|
|||
|
Total liabilities and stockholders’ equity
|
$
|
726,245
|
|
$
|
756,312
|
|
|
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
5
ALIGN TECHNOLOGY, INC.
(in thousands)
(unaudited)
|
|
Three Months Ended
|
||||||
|
March 31,
|
|||||||
|
|
2013
|
2012
|
|||||
|
CASH FLOWS FROM OPERATING ACTIVITIES:
|
Revised*
|
||||||
|
Net income (loss)
|
$
|
(41,983
|
)
|
$
|
20,984
|
|
|
|
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
|
|||||||
|
Deferred taxes
|
931
|
|
4,726
|
|
|||
|
Depreciation and amortization
|
3,855
|
|
2,753
|
|
|||
|
Amortization of intangibles
|
1,089
|
|
1,146
|
|
|||
|
Stock-based compensation
|
6,410
|
|
4,863
|
|
|||
|
Excess tax benefit from share-based payment arrangements
|
(7,739
|
)
|
(8,043
|
)
|
|||
|
Impairment of goodwill
|
40,693
|
|
—
|
|
|||
|
Impairment of long-lived assets
|
26,320
|
|
—
|
|
|||
|
Recovery of doubtful accounts and returns
|
(1,196
|
)
|
(119
|
)
|
|||
|
Other
|
(10
|
)
|
52
|
|
|||
|
Changes in assets and liabilities:
|
|||||||
|
Accounts receivable
|
(9,240
|
)
|
(2,398
|
)
|
|||
|
Inventories
|
(320
|
)
|
(4,030
|
)
|
|||
|
Prepaid expenses and other assets
|
(586
|
)
|
(1,530
|
)
|
|||
|
Accounts payable
|
1,611
|
|
(3,641
|
)
|
|||
|
Accrued and other long-term liabilities
|
(7,941
|
)
|
(9,191
|
)
|
|||
|
Deferred revenues
|
(1,476
|
)
|
1,809
|
|
|||
|
Net cash provided by operating activities
|
10,418
|
|
7,381
|
|
|||
|
CASH FLOWS FROM INVESTING ACTIVITIES:
|
|||||||
|
Release of restricted cash
|
1,053
|
|
3
|
|
|||
|
Purchase of property, plant and equipment
|
(5,608
|
)
|
(12,559
|
)
|
|||
|
Purchase of marketable securities
|
(3,282
|
)
|
(28,190
|
)
|
|||
|
Maturities of marketable securities
|
4,366
|
|
2,751
|
|
|||
|
Other assets
|
26
|
|
—
|
|
|||
|
Net cash used in investing activities
|
(3,445
|
)
|
(37,995
|
)
|
|||
|
CASH FLOWS FROM FINANCING ACTIVITIES:
|
|||||||
|
Proceeds from issuance of common stock
|
13,268
|
|
10,180
|
|
|||
|
Common stock repurchase
|
(2,438
|
)
|
(2,524
|
)
|
|||
|
Excess tax benefit from share-based payment arrangements
|
7,739
|
|
8,043
|
|
|||
|
Employees’ taxes paid upon the vesting of restricted stock units
|
(3,141
|
)
|
(1,408
|
)
|
|||
|
Other
|
(5
|
)
|
—
|
|
|||
|
Net cash provided by financing activities
|
15,423
|
|
14,291
|
|
|||
|
Effect of foreign exchange rate changes on cash and cash equivalents
|
(37
|
)
|
9
|
|
|||
|
Net increase (decrease) in cash and cash equivalents
|
22,359
|
|
(16,314
|
)
|
|||
|
Cash and cash equivalents, beginning of the period
|
306,386
|
|
240,675
|
|
|||
|
Cash and cash equivalents, end of the period
|
$
|
328,745
|
|
$
|
224,361
|
|
|
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
*See Note 1 of Condensed Consolidated Financial Statements.
6
ALIGN TECHNOLOGY, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
Basis of presentation
The accompanying unaudited Condensed Consolidated Financial Statements have been prepared by Align Technology, Inc. (“we”, “our”, or “Align”) in accordance with the rules and regulations of the Securities and Exchange Commission (SEC) and contain all adjustments, including normal recurring adjustments, necessary to present fairly our results of operations for the
three
months ended
March 31, 2013
and
2012
, our comprehensive income (loss) for the
three
months ended
March 31, 2013
and
2012
, our financial position as of
March 31, 2013
and our cash flows for the
three
months ended
March 31, 2013
and
2012
. The Condensed Consolidated Balance Sheet as of
December 31, 2012
was derived from the
December 31, 2012
audited financial statements.
The results of operations for the
three
months ended
March 31, 2013
are not necessarily indicative of the results that may be expected for the year ending
December 31, 2013
or any other future period, and we make no representations related thereto. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” “Quantitative and Qualitative Disclosures About Market Risk” and the Consolidated Financial Statements and notes thereto included in Items 7, 7A and 8, respectively, in our Annual Report on Form 10-K for the year ended
December 31, 2012
.
Use of estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S.”) requires our management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates. On an ongoing basis, we evaluate our estimates, including those related to the fair values of financial instruments, long-lived assets and goodwill, useful lives of intangible assets and property and equipment, stock-based compensation, income taxes, and contingent liabilities, among others. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities.
Revision of Prior Period Financial Statements
In connection with the preparation of our consolidated financial statements for the third quarter of 2012, we determined that we had not correctly recognized the excess tax benefits related to stock-based awards in the first quarter of 2012.
In accordance with Staff Accounting Bulletin (SAB) No. 99, “Materiality”, and SAB No. 108, “Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements”, we evaluated the materiality of the errors from qualitative and quantitative perspectives, and evaluated the quantified errors under both the iron curtain and the roll-over methods. We concluded that the errors were not material to the financial statements for the first quarter of 2012 and revised the presentation of the statement of cash flows for the first quarter of 2012.
The following tables summarize the effects of the revision on our Condensed Consolidated Statement of Cash Flows. The revision did not impact our Condensed Consolidated Statement of Operations for the first quarter of 2012.
7
Cash flows
|
Three Months Ended March 31, 2012
|
||||||||||||
|
(in thousands)
|
||||||||||||
|
Previously Reported
|
Adjustment
|
As Revised
|
||||||||||
|
Statement of Cash Flows
|
||||||||||||
|
Net cash provided by operating activities
|
$
|
15,424
|
|
$
|
(8,043
|
)
|
$
|
7,381
|
|
|||
|
Net cash provided by financing activities
|
6,248
|
|
8,043
|
|
14,291
|
|
||||||
|
Net decrease in cash and cash equivalents
|
(16,314
|
)
|
—
|
|
(16,314
|
)
|
||||||
Recent Accounting Pronouncements
In February 2013, the FASB issued ASU 2013-02, “Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income ("AOCI")” . This standard requires reporting, in one place, information about reclassifications out of AOCI by component. An entity is required to present, either on the face of the financial statements or in the notes, significant amounts reclassified out of AOCI by the respective line items of net income, but only if the amount is reclassified in its entirety in the same reporting period. For amounts that are not required to be reclassified to net income in their entirety, an entity is required to cross-reference to other currently required disclosures that provide additional detail about those amounts. The information required by this standard must be presented in one place, either parenthetically on the face of the financial statements by income statement line item or in a note. The adoption of this guidance during the period ended March 31, 2013 did not have a material affect to our condensed consolidated financial statements.
Our short-term and long-term marketable securities as of
March 31, 2013
and
December 31, 2012
are as follows (in thousands):
Short-term
|
March 31, 2013
|
Amortized
Cost
|
Gross
Unrealized
Gains
|
Gross
Unrealized
Losses
|
Fair Value
|
|||||||||||
|
Corporate bonds
|
27,145
|
|
21
|
|
(2
|
)
|
27,164
|
|
|||||||
|
U.S. dollar dominated foreign corporate bonds
|
8,052
|
|
10
|
|
—
|
|
8,062
|
|
|||||||
|
Commercial paper
|
2,749
|
|
—
|
|
—
|
|
2,749
|
|
|||||||
|
Total
|
$
|
37,946
|
|
$
|
31
|
|
$
|
(2
|
)
|
$
|
37,975
|
|
|||
Long-term
|
March 31, 2013
|
Amortized
Cost
|
Gross
Unrealized
Gains
|
Gross
Unrealized
Losses
|
Fair Value
|
|||||||||||
|
Corporate bonds
|
$
|
7,592
|
|
$
|
2
|
|
$
|
(4
|
)
|
$
|
7,590
|
|
|||
|
U.S. government agency bonds
|
2,066
|
|
2
|
|
—
|
|
2,068
|
|
|||||||
|
U.S. dollar dominated foreign corporate bonds
|
1,023
|
|
—
|
|
(1
|
)
|
1,022
|
|
|||||||
|
Total
|
$
|
10,681
|
|
$
|
4
|
|
$
|
(5
|
)
|
$
|
10,680
|
|
|||
8
Short-term
|
December 31, 2012
|
Amortized
Cost
|
Gross
Unrealized
Gains
|
Gross
Unrealized
Losses
|
Fair Value
|
|||||||||||
|
Corporate bonds
|
$
|
18,767
|
|
$
|
7
|
|
$
|
(4
|
)
|
$
|
18,770
|
|
|||
|
Commercial paper
|
4,646
|
|
1
|
|
—
|
|
4,647
|
|
|||||||
|
U.S. dollar dominated foreign corporate bonds
|
5,060
|
|
9
|
|
(1
|
)
|
5,068
|
|
|||||||
|
Total
|
$
|
28,473
|
|
$
|
17
|
|
$
|
(5
|
)
|
$
|
28,485
|
|
|||
Long-term
|
December 31, 2012
|
Amortized
Cost
|
Gross
Unrealized
Gains
|
Gross
Unrealized
Losses
|
Fair
Value
|
|||||||||||
|
Corporate bonds
|
16,132
|
|
16
|
|
(7
|
)
|
16,141
|
|
|||||||
|
U.S. government agency bonds
|
$
|
2,069
|
|
$
|
1
|
|
$
|
—
|
|
$
|
2,070
|
|
|||
|
U.S. dollar dominated foreign corporate bonds
|
3,038
|
|
4
|
|
(1
|
)
|
3,041
|
|
|||||||
|
Total
|
$
|
21,239
|
|
$
|
21
|
|
$
|
(8
|
)
|
$
|
21,252
|
|
|||
For the three months ended March 31, 2013 and 2012, realized losses were immaterial. Unrealized gains and losses for our available for sale securities as of March 31, 2013 and December 31, 2012 were also immaterial. Cash and cash equivalents were not included in the table above as the gross unrealized gains and losses were not material. We have no material short-term or long-term investments that have been in a continuous unrealized loss position for greater than twelve months as of March 31, 2013 and December 31, 2012. Amounts reclassified to earnings from accumulated other comprehensive income related to unrealized gain or losses were immaterial for the three months ended March 31, 2013 and 2012.
Our fixed-income securities investment portfolio consists of corporate bonds, U.S. government agency bonds, U.S. dollar dominated foreign corporate bonds and commercial paper that have a maximum maturity of
two
years. The corporate debt and government and agency securities that we invest in are generally deemed to be low risk based on their credit ratings from the major rating agencies. The longer the duration of these securities, the more susceptible they are to changes in market interest rates and bond yields. As interest rates increase, those securities purchased at a lower yield show a mark-to-market unrealized loss. The unrealized losses are due primarily to changes in credit spreads and interest rates. We expect to realize the full value of all these investments upon maturity or sale. As of
March 31, 2013
and December 31, 2012, these securities had a weighted average remaining duration of approximately
6 months
and
10 months
, respectively.
|
March 31,
|
December 31,
|
||||||
|
2013
|
2012
|
||||||
|
(in thousands)
|
(in thousands)
|
||||||
|
One year or less
|
$
|
37,975
|
|
$
|
28,485
|
|
|
|
One year through two years
|
10,680
|
|
21,252
|
|
|||
|
Total available for sale securities
|
$
|
48,655
|
|
$
|
49,737
|
|
|
Fair Value Measurements
We measure the fair value of our cash equivalents and marketable securities as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. We use the GAAP fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. This hierarchy requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of inputs that may be used to measure fair value:
Level 1
—Quoted (unadjusted) prices in active markets for identical assets or liabilities.
Our Level 1 assets consist of money market funds. We did not hold any Level 1 liabilities as of
March 31, 2013
.
9
Level 2
—Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability.
Our Level 2 assets consist of commercial paper, corporate bonds, foreign bonds, agency bonds, and our Israeli severance funds that are mainly invested in insurance policies. We obtain these fair values for level 2 investments from our asset manager for each of our portfolios. Our custody bank and asset managers independently use professional pricing services to gather pricing data which may include quoted market prices for identical or comparable financial instruments, or inputs other than quoted prices that are observable either directly or indirectly, and we are ultimately responsible for these underlying estimates.
We did not hold any Level 2 liabilities as of
March 31, 2013
.
Level 3
—Unobservable inputs to the valuation methodology that are supported by little or no market activity and that are significant to the measurement of the fair value of the assets or liabilities. Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques, as well as significant management judgment or estimation.
We did not hold any Level 3 assets or liabilities as of
March 31, 2013
.
Non-Recurring Fair Value Measurements
During the first quarter 2013, we recorded an impairment charge to our long-lived assets and goodwill for
$26.3 million
and
$40.7 million
, respectively, related to our SCCS reporting unit as an event occurred or circumstances changed that led us to perform an impairment analysis between the annual test which required us to determine the fair value of the SCCS reporting unit (Refer to Note 4). These fair value measurements were calculated using unobservable inputs, using the income approach which is classified as Level 3 within the fair value hierarchy. Inputs for the income approach includes the amount and timing of future cash flows based on our most recent operational budgets, strategic plans, terminal growth rates assumptions and other estimates.
The following table summarizes our financial assets measured at fair value on a recurring basis as of
March 31, 2013
(in thousands):
|
Description
|
Balance as of
March 31, 2013
|
Quoted Prices in
Active Markets for
Identical Assets
(Level 1)
|
Significant Other
Observable Inputs
(Level 2)
|
||||||||
|
Cash equivalents:
|
|||||||||||
|
Money market funds
|
$
|
258,819
|
|
$
|
258,819
|
|
$
|
—
|
|
||
|
Commercial paper
|
500
|
|
—
|
|
500
|
|
|||||
|
Short-term investments:
|
|||||||||||
|
Commercial paper
|
2,749
|
|
—
|
|
2,749
|
|
|||||
|
Corporate bonds
|
27,164
|
|
—
|
|
27,164
|
|
|||||
|
U.S. dollar dominated foreign corporate bonds
|
8,062
|
|
—
|
|
8,062
|
|
|||||
|
Long-term investments:
|
|||||||||||
|
Corporate bonds
|
7,590
|
|
—
|
|
7,590
|
|
|||||
|
U.S. government agency bonds
|
2,068
|
|
—
|
|
2,068
|
|
|||||
|
U.S. dollar dominated foreign corporate bonds
|
1,022
|
|
—
|
|
1,022
|
|
|||||
|
Other assets:
|
|||||||||||
|
Israeli severance funds
|
2,265
|
|
—
|
|
2,265
|
|
|||||
|
$
|
310,239
|
|
$
|
258,819
|
|
$
|
51,420
|
|
|||
10
The following table summarizes our financial assets measured at fair value on a recurring basis as of
December 31, 2012
(in thousands):
|
Description
|
Balance as of
December 31, 2012
|
Quoted Prices in
Active Markets for
Identical Assets
(Level 1)
|
Significant Other
Observable Inputs
(Level 2)
|
||||||||
|
Cash equivalents:
|
|||||||||||
|
Money market funds
|
$
|
86,166
|
|
$
|
86,166
|
|
$
|
—
|
|
||
|
Commercial paper
|
950
|
|
—
|
|
950
|
|
|||||
|
Short-term investments:
|
|||||||||||
|
Commercial paper
|
4,647
|
|
—
|
|
4,647
|
|
|||||
|
Corporate bonds
|
18,770
|
|
—
|
|
18,770
|
|
|||||
|
U.S. government agency bonds
|
5,068
|
|
—
|
|
5,068
|
|
|||||
|
Long-term investments:
|
|||||||||||
|
U.S. government agency bonds
|
2,070
|
|
—
|
|
2,070
|
|
|||||
|
Corporate bonds
|
16,141
|
|
—
|
|
16,141
|
|
|||||
|
U.S. dollar denominated foreign corporate bonds
|
3,041
|
|
—
|
|
3,041
|
|
|||||
|
Other assets:
|
|||||||||||
|
Israeli severance funds
|
2,218
|
|
—
|
|
2,218
|
|
|||||
|
$
|
139,071
|
|
$
|
86,166
|
|
$
|
52,905
|
|
|||
Inventories
Inventories are comprised of (in thousands):
|
March 31,
2013 |
December 31,
2012 |
||||||
|
Raw materials
|
$
|
7,381
|
|
$
|
7,629
|
|
|
|
Work in process
|
3,196
|
|
3,889
|
|
|||
|
Finished goods
|
4,865
|
|
3,604
|
|
|||
|
$
|
15,442
|
|
$
|
15,122
|
|
||
Work in process includes costs to produce our clear aligner and intra-oral scanner products. Finished goods primarily represent our intra-oral scanners and ancillary products that support our clear aligner products.
11
Accrued liabilities
Accrued liabilities consist of the following (in thousands):
|
March 31,
2013 |
December 31,
2012 |
||||||
|
Accrued payroll and benefits
|
$
|
31,246
|
|
$
|
39,621
|
|
|
|
Accrued sales rebate
|
8,996
|
|
8,333
|
|
|||
|
Accrued sales tax and value added tax
|
4,890
|
|
5,253
|
|
|||
|
Accrued sales and marketing expenses
|
3,695
|
|
4,088
|
|
|||
|
Accrued warranty
|
4,129
|
|
4,050
|
|
|||
|
Accrued accounts payable
|
2,230
|
|
2,866
|
|
|||
|
Accrued distributor expenses
|
2,300
|
|
1,800
|
|
|||
|
Accrued professional fees
|
1,207
|
|
2,349
|
|
|||
|
Unclaimed merger consideration
|
508
|
|
1,575
|
|
|||
|
Accrued income taxes
|
595
|
|
572
|
|
|||
|
Other
|
4,839
|
|
3,740
|
|
|||
|
Total
|
$
|
64,635
|
|
$
|
74,247
|
|
|
Warranty
We regularly review the accrued balances and update these balances based on historical warranty trends. Actual warranty costs incurred have not materially differed from those accrued. However, future actual warranty costs could differ from the estimated amounts.
Clear Aligner
We warrant our Invisalign products against material defects until the Invisalign case is complete. We accrue for warranty costs in cost of net revenues upon shipment of products. The amount of accrued estimated warranty costs is primarily based on historical experience as to product failures as well as current information on replacement costs.
Scanners
We warrant our scanners for a period of
one
year from the date of training and installation. We accrue for these warranty costs which includes materials and labor based on estimated historical repair costs. Extended service packages may be purchased for additional fees.
The following table reflects the change in our warranty accrual during the three months ended
March 31, 2013
and
2012
, respectively (in thousands):
|
|
Three Months Ended
March 31,
|
||||||
|
|
2013
|
2012
|
|||||
|
Balance at beginning of period
|
$
|
4,050
|
|
$
|
3,177
|
|
|
|
Charged to cost of revenues
|
1,263
|
|
888
|
|
|||
|
Actual warranty expenditures
|
(1,184
|
)
|
(914
|
)
|
|||
|
Balance at end of period
|
$
|
4,129
|
|
$
|
3,151
|
|
|
Goodwill
The change in the carrying value of goodwill for the quarter ended
March 31, 2013
by our reportable segments, which are also our reporting units, are as follows (in thousands):
12
|
Clear Aligner
|
Scanners and
CAD/CAM
Services
|
Total
|
|||||||||
|
Balance as of December 31, 2012
|
$
|
58,543
|
|
$
|
40,693
|
|
$
|
99,236
|
|
||
|
Impairment of goodwill
|
—
|
|
(40,693
|
)
|
(40,693
|
)
|
|||||
|
Balance as of March 31, 2013
|
$
|
58,543
|
|
$
|
—
|
|
$
|
58,543
|
|
||
Impairment of Goodwill
We test our goodwill balances for impairment annually on November 30th or more frequently if indicators are present or circumstances change that suggest it is more likely than not that the fair value of the reporting unit is less than the carrying amount. During March of 2013, changes in the competitive environment for intra-oral scanners, including announcements from our competitors of new low-priced scanners targeted at Orthodontist and GP Dentist in North America, that caused us to lower our expectations for growth and profitability for our Scanner and CAD/CAM Services (SCCS) reporting unit. As a result, we determined that goodwill for our SCCS reporting unit should be tested for impairment as of March 2013 due to these facts and circumstances which would more likely than not reduce the fair value of our SCCS reporting unit below its carrying amount.
We performed a step one analysis for our SCCS reporting unit which consists of a comparison of the fair value of the SCCS reporting unit against its carrying amount, including the goodwill allocated to it. In deriving the fair value of the SCCS reporting unit, we utilized the income approach which is classified as Level 3 within the fair value hierarchy. This approach provides an estimated fair value based on discounted expected future cash flows, which are based on management's estimates of revenue growth rates and operating margins, taking into consideration industry and market conditions. The discount rate used is based on a weighted average cost of capital adjusted for the relevant risk associated with the characteristics of the business and the projected cash flows.
As a result of our step one analysis, we concluded that the fair value of the SCCS reporting unit was less than its carrying value, therefore we proceeded to step two of the goodwill impairment analysis. Step two of the goodwill impairment analysis measures the impairment charge by allocating the reporting unit's fair value to all of the assets and liabilities of the reporting unit in a hypothetical analysis that calculates the implied fair value of goodwill in the same manner as if the reporting unit was being acquired in a business combination. This allocation process was performed only for the purposes of measuring the goodwill impairment, and not to adjust the carrying values of the recognized tangible assets and liabilities. Any excess of the carrying value of the reporting unit's goodwill over the implied fair value of the reporting unit's goodwill is recorded as an impairment loss. Based on our analysis, there was no implied goodwill for the SCCS reporting unit. We therefore recorded a goodwill impairment charge of
$40.7 million
which represents the remaining goodwill balance in the scanner and CAD/CAM services reporting unit. None of the goodwill impairment charge was deductible for tax purposes.
Long-lived Assets
Impairment of Long-lived Assets
We amortize our intangible assets over their estimated useful lives. We evaluate long-lived assets, which includes plant and equipment and intangible assets, for impairment whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. The carrying value is not recoverable if it exceeds the undiscounted cash flows resulting from the use of the asset and its eventual disposition. Our estimates of future cash flows attributable to our long-lived assets require significant judgment based on our historical and anticipated results and are subject to many factors. Factors we consider important which could trigger an impairment review include significant negative industry or economic trends, significant loss of customers, and changes the competitive environment in the intra-oral scanning business.
During March of 2013, changes in the competitive environment for intra-oral scanners, including announcements of new low-priced scanners targeted at Orthodontists and GP Dentists in North America, caused us to lower our expectations for growth and profitability for our SCCS reporting unit. As a result, we determined that the carrying value of the long-lived assets was not recoverable as compared to the value of the undiscounted cash flows of our revised projections for the asset group. In order to determine the impairment amount of our long-lived assets, we fair valued each key component of our long-lived assets within the asset group, which involved the use of significant estimates and assumptions including replacement costs, revenue growth rates, operating margins, and plant and equipment cost trends. We determined our long-lived asset group within the SCCS reporting unit to be primarily finite-lived intangible assets, plant and equipment. Upon completion of this analysis, we recorded a total impairment charge of
$26.3 million
of which
$19.3 million
represented the impairment related to our SCCS intangible assets and
$7.0 million
related to plant and equipment.
13
Intangible assets arising either as a direct result from the Cadent acquisition or individually acquired are being amortized as follows (in thousands):
|
Weighted Average Amortization Period (in years)
|
Gross Carrying Amount as of
March 31, 2013
|
Accumulated
Amortization
|
Accumulated
Impairment Loss
|
Net Carrying
Value as of
March 31, 2013
|
|||||||||||||
|
Trademarks
|
15
|
$
|
7,100
|
|
$
|
(1,015
|
)
|
$
|
(4,179
|
)
|
$
|
1,906
|
|
||||
|
Existing technology
|
13
|
12,600
|
|
(1,860
|
)
|
(4,328
|
)
|
6,412
|
|
||||||||
|
Customer relationships
|
11
|
33,500
|
|
(5,749
|
)
|
(10,751
|
)
|
17,000
|
|
||||||||
|
Other
|
7
|
125
|
|
(14
|
)
|
—
|
|
111
|
|
||||||||
|
$
|
53,325
|
|
$
|
(8,638
|
)
|
$
|
(19,258
|
)
|
$
|
25,429
|
|
||||||
The total estimated annual future amortization expense for these acquired intangible assets as of
March 31, 2013
is as follows (in thousands):
|
Fiscal Year
|
|
||
|
2013 (remaining nine months)
|
$
|
1,971
|
|
|
2014
|
2,616
|
|
|
|
2015
|
2,610
|
|
|
|
2016
|
2,610
|
|
|
|
2017
|
2,610
|
|
|
|
Thereafter
|
13,012
|
|
|
|
Total
|
$
|
25,429
|
|
On March 22, 2013, we entered into a credit facility with Wells Fargo Bank. The credit facility provides for a
$50.0 million
revolving credit line of credit, with a
$10.0 million
letter of credit sublimit, with a maturity date on March 22, 2016. The credit facility also requires us to maintain a minimum unrestricted cash balance of
$50.0 million
and comply with specific financial conditions and performance. The loans bear interest, at our option, at a fluctuating rate per annum equal to the daily one-month adjusted LIBOR rate plus a spread of
1.75%
or an adjusted LIBOR rate (based on one, three, six or twelve-month interest periods) plus a spread of
1.75%
. As of March 31, 2013, we had
no
outstanding borrowings under this credit facility and were in compliance with the conditions and performance.
Securities Class Action Lawsuit
On November 28, 2012, plaintiff City of Dearborn Heights Act 345 Police & Fire Retirement System filed a lawsuit against Align, Thomas M. Prescott (“Mr. Prescott”), Align's President and Chief Executive Officer, and Kenneth B. Arola (“Mr. Arola”), Align's former Vice President, Finance and Chief Financial Officer, in the United States District Court for the Northern District of California on behalf of a purported class of purchasers of our common stock between April 23, 2012 and October 17, 2012 ( the "Securities Action"). The complaint alleges that Align, Mr. Prescott and Mr. Arola violated Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, and that Mr. Prescott and Mr. Arola violated Section 20(a) of the Securities Exchange Act of 1934. Specifically, the complaint alleges that during the purported class period our reported income and earnings were materially overstated because of a failure to timely write down goodwill related to the April 29, 2011 acquisition of Cadent Holdings, Inc., and that defendants made allegedly false statements concerning our forecasts. The complaint seeks monetary damages in an unspecified amount, costs and attorney's fees. The hearing on the motion for appointment of lead plaintiff is currently scheduled for May 30th, 2013. Align intends to vigorously defend itself against these allegations. Align is currently unable to predict the outcome of this complaint and therefore cannot determine the likelihood of loss nor estimate a range of possible loss.
Shareholder Derivative Lawsuit
14
On February 1, 2013, plaintiff Gary Udis filed a shareholder derivative lawsuit against several of Align's current and former officers and directors in the Superior Court of California, County of Santa Clara. The allegations in the complaint are similar to those presented in the Securities Action, but the complaint asserts various state law causes of action, including claims of breach of fiduciary duty, unjust enrichment, and insider trading, among others. The complaint seeks unspecified damages on behalf of Align, which is named solely as nominal defendant against whom no recovery is sought. The complaint also seeks an order directing Align to reform and improve its corporate governance and internal procedures, and seeks restitution in an unspecified amount, costs, and attorney's fees. Align intends to vigorously defend itself against these allegations. Align is currently unable to predict the outcome of this complaint and therefore cannot determine the likelihood of loss nor estimate a range of possible losses.
In addition, in the course of Align's operations, Align is involved in a variety of claims, suits, investigations, and proceedings, including actions with respect to intellectual property claims, patent infringement claims, government investigations, labor and employment claims, breach of contract claims, tax, and other matters. Regardless of the outcome, these proceedings can have an adverse impact on us because of defense costs, diversion of management resources, and other factors. Although the results of complex legal proceedings are difficult to predict and Align's view of these matters may change in the future as litigation and events related thereto unfold; Align currently does not believe that these matters, individually or in the aggregate, will materially affect Align's financial position, results of operations or cash flows.
Operating Leases
As of
March 31, 2013
, minimum future lease payments for non-cancelable leases are as follows (in thousands):
|
Fiscal Year
|
Operating leases
|
|||
|
2013 (remaining nine months)
|
$
|
5,231
|
|
|
|
2014
|
6,421
|
|
||
|
2015
|
5,139
|
|
||
|
2016
|
4,779
|
|
||
|
2017
|
2,245
|
|
||
|
Total minimum lease payments
|
$
|
23,815
|
|
|
Off-balance Sheet Arrangements
As of
March 31, 2013
, we had no off-balance sheet arrangements that have, or are reasonably likely to have, a current or future material effect on our consolidated financial condition, results of operations, liquidity, capital expenditures or capital resources.
Indemnification Provisions
In the normal course of business to facilitate transactions in our services and products, we indemnify certain parties: customers, vendors, lessors, and other parties with respect to certain matters, including, but not limited to, services to be provided by us and intellectual property infringement claims made by third parties. In addition, we have entered into indemnification agreements with our directors and certain of our officers that will require us, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. Several of these agreements limit the time within which an indemnification claim can be made and the amount of the claim.
It is not possible to make a reasonable estimate of the maximum potential amount under these indemnification agreements due to the unique facts and circumstances involved in each particular agreement. Additionally, we have a limited history of prior indemnification claims and the payments we have made under such agreements have not had a material adverse effect on our results of operations, cash flows, or financial position. However, to the extent that valid indemnification claims arise in the future, future payments by us could be significant and could have a material adverse effect on our results of operations or cash flows in a particular period. As of
March 31, 2013
, we did not have any material indemnification claims that were probable or reasonably possible.
15
Summary of stock-based compensation expense
On May 19, 2011 the Shareholders approved an increase of
3,000,000
shares to the 2005 Incentive Plan (as amended) for a total reserve of
16,283,379
shares for issuance, plus up to an aggregate of
5,000,000
shares that would have been returned to our 2001 Stock Incentive Plan as a result of termination of options on or after March 28, 2005.
Stock-based compensation expense is based on the estimated fair value of awards, net of estimated forfeitures and recognized over the requisite service period. Estimated forfeitures are based on historical experience at the time of grant and may be revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The stock-based compensation expense related to all of our stock-based awards and employee stock purchases for the three months ended
March 31, 2013
and 2012 are as follows (in thousands):
|
|
Three Months Ended
March 31,
|
||||||
|
|
2013
|
2012
|
|||||
|
Cost of net revenues
|
$
|
580
|
|
$
|
463
|
|
|
|
Sales and marketing
|
1,011
|
|
1,171
|
|
|||
|
General and administrative
|
3,927
|
|
2,429
|
|
|||
|
Research and development
|
892
|
|
800
|
|
|||
|
Total stock-based compensation expense
|
$
|
6,410
|
|
$
|
4,863
|
|
|
Options
Activity for the
three
month period ended
March 31, 2013
under the stock option plans are set forth below (in thousands, except years and per share amounts):
|
Stock Options
Number of
Shares
Underlying
Stock Options
|
Weighted
Average
Exercise
Price per Share
|
Weighted Average
Remaining
Contractual Term
(in years )
|
Aggregate
Intrinsic
Value
|
|||||||||
|
Outstanding as of December 31, 2012
|
3,276
|
|
||||||||||
|
Granted
|
—
|
|
||||||||||
|
Exercised
|
(660
|
)
|
||||||||||
|
Cancelled or expired
|
(65
|
)
|
||||||||||
|
Outstanding as of March 31, 2013
|
2,551
|
|
$
|
15.46
|
|
4.04
|
$
|
46,054
|
|
|||
|
Vested and expected to vest at March 31, 2013
|
2,535
|
|
$
|
15.43
|
|
4.03
|
$
|
45,826
|
|
|||
|
Exercisable at March 31, 2013
|
2,158
|
|
$
|
14.85
|
|
3.97
|
$
|
40,263
|
|
|||
There were
no
stock options granted during the three months ended
March 31, 2013
and 2012.
As of
March 31, 2013
, the total unamortized compensation cost related to stock options, net of estimated forfeitures, is
$3.9 million
, which we expect to recognize over a weighted average period of
1.3
years.
Restricted Stock Units (“RSUs”)
A summary of the nonvested shares for the
three
months ended
March 31, 2013
is as follows (in thousands, except years):
|
Number of Shares
Underlying RSUs
|
Weighted Remaining
Vesting Period
|
Aggregate
Intrinsic Value
|
||||||
|
|
|
(in years)
|
|
|||||
|
Nonvested as of December 31, 2012
|
1,500
|
|
||||||
|
Granted
|
852
|
|
||||||
|
Vested and released
|
(388
|
)
|
||||||
|
Forfeited
|
(58
|
)
|
||||||
|
Nonvested as of March 31, 2013
|
1,906
|
|
1.90
|
$
|
63,882
|
|
||
16
As of
March 31, 2013
the total unamortized compensation cost related to restricted stock units, net of estimated forfeitures, was
$44.2 million
, which we expect to recognize over a weighted average period of
3.0
years.
On February 20, 2013 and 2012, we granted market-performance based restricted stock units (“MSUs”) to our executive officers. Each MSU represents the right to one share of Align’s common stock and will be issued through our amended 2005 Incentive Plan. The actual number of MSUs which will be eligible to vest will be based on the performance of Align’s stock price relative to the performance of the NASDAQ Composite Index over the vesting period, generally
two
to
three
years, up to
150%
of the MSUs initially granted.
The following table summarizes the MSU performance for the
three
months ended
March 31, 2013
(in thousands, except years):
|
Number of Shares
Underlying MSUs
|
Weighted Average
Remaining
Vesting Period
|
Aggregate
Intrinsic Value
|
||||||
|
|
(in years )
|
|||||||
|
Nonvested as of December 31, 2012
|
266
|
|
||||||
|
Granted
|
220
|
|
||||||
|
Vested and released
|
(79
|
)
|
||||||
|
Forfeited
|
(32
|
)
|
||||||
|
Nonvested as of March 31, 2013
|
375
|
|
2.30
|
$
|
12,553
|
|
||
As of
March 31, 2013
, we expect to recognize
$8.8 million
of total unamortized compensation cost, net of estimated forfeitures, related to MSU over a weighted average period of
2.0
years.
Employee Stock Purchase Plan
In May 2010, our shareholders approved the 2010 Employee Stock Purchase Plan (the “2010 Purchase Plan”) to replace the 2001 Purchase Plan. The terms and features of the 2010 Purchase Plan are substantially the same as the 2001 Purchase Plan and will continue until terminated by either the Board or its administrator. The maximum number of shares available for purchase under the 2010 Purchase Plan is
2,400,000
shares. As of
March 31, 2013
, there remains
1,738,963
shares available for purchase under the 2010 Purchase Plan.
The fair value of the option component of the Purchase Plan shares was estimated at the grant date using the Black-Scholes option pricing model with the following weighted average assumptions:
|
|
Three Months Ended March 31,
|
||||||
|
|
2013
|
2012
|
|||||
|
Employee Stock Purchase Plan:
|
|||||||
|
Expected term (in years)
|
1.2
|
|
1.2
|
|
|||
|
Expected volatility
|
46.7
|
%
|
53.7
|
%
|
|||
|
Risk-free interest rate
|
0.2
|
%
|
0.2
|
%
|
|||
|
Expected dividends
|
—
|
|
—
|
|
|||
|
Weighted average fair value at grant date
|
$
|
11.17
|
|
$
|
9.08
|
|
|
As of
March 31, 2013
, we expect to recognize
$3.4 million
of the total unamortized compensation cost related to employee purchases over a weighted average period of
1
year.
17
On October 27, 2011, we announced that our Board of Directors approved a stock repurchase program pursuant to which we may repurchase up to
$150.0 million
of common stock. Purchases under the stock repurchase program may be made from time to time in the open market. During the first quarter of 2013, we repurchased approximately
0.1 million
shares of common stock at an average price of
$32.47
per share for an aggregate purchase price of approximately
$2.4 million
including commissions. The common stock repurchases reduced additional paid-in capital by approximately
$0.7 million
and increased accumulated deficit by
$1.7 million
. All repurchased shares were retired. As of
March 31, 2013
, there remains approximately
$92.6 million
available under our existing stock repurchase authorization.
For the three months ended March 31, 2013 and 2012, the Company's tax expense was
$2.9 million
and
$6.2 million
, respectively, representing effective tax rates of
(7.5)%
and
22.8%
. The effective tax rate decreased primarily due to a jurisdictional shift in forecasted earnings from the U.S. to lower-tax non-U.S. jurisdictions, as well as the impact of the impairment of goodwill and long-lived assets for the three months ended March 31, 2013.
During the first quarter of fiscal 2013, the amount of gross unrecognized tax benefits increased by approximately
$1.4 million
primarily due to current period exposures. The total amount of unrecognized tax benefits was
$22.1 million
as of
March 31, 2013
, all of which would impact our effective tax rate if recognized. We have elected to recognize interest and penalties related to unrecognized tax benefits as a component of income taxes. The change in accrued interest and penalties during the first quarter of fiscal year 2013 was not material. We do not expect any significant changes to the amount of unrecognized tax benefit within the next twelve months.
We are subject to taxation in the U.S., and various states and foreign jurisdictions. All of our tax years will be open to examination by the U.S. federal and most state tax authorities due to our net operating loss and overall credit carryforward position. With few exceptions, we are no longer subject to examination by foreign tax authorities for years before 2006.
Basic net income per share is computed using the weighted average number of shares of common stock outstanding during the period. Diluted net income per share is computed using the weighted average number of shares of common stock, adjusted for the dilutive effect of potential common stock. Potential common stock, computed using the treasury stock method, includes options, RSUs, MSUs and our employee stock purchase plan ("ESPP").
The following table sets forth the computation of basic and diluted net income (loss) per share attributable to common stock (in thousands, except per share amounts):
|
|
Three Months Ended,
March 31,
|
||||||
|
|
2013
|
2012
|
|||||
|
Numerator:
|
|||||||
|
Net income (loss)
|
$
|
(41,983
|
)
|
$
|
20,984
|
|
|
|
Denominator:
|
|||||||
|
Weighted-average common shares outstanding, basic
|
81,248
|
|
79,235
|
|
|||
|
Dilutive effect of potential common stock
|
—
|
|
2,621
|
|
|||
|
Total shares, diluted
|
81,248
|
|
81,856
|
|
|||
|
Net income (loss) per share, basic
|
$
|
(0.52
|
)
|
$
|
0.26
|
|
|
|
Net income (loss) per share, diluted
|
$
|
(0.52
|
)
|
$
|
0.26
|
|
|
For the three months ended March 31 ,2013, stock options, RSUs, MSUs and ESPP totaling
1.8 million
of potentially dilutive shares have been excluded from the total diluted shares because there was a net loss for the period.
For the
three
months ended March 31, 2012, stock options, RSUs and MSUs totaling
0.8 million
were excluded from diluted net income per share because of their anti-dilutive effect.
18
Segment Information
Operating segments are defined as components of an enterprise for which separate financial information is available that is evaluated regularly by the Chief Operating Decision Maker (“CODM”), or decision-making group, in deciding how to allocate resources and in assessing performance. Our CODM is our Chief Executive Officer. We report segment information based on the management approach. The management approach designates the internal reporting used by CODM for decision making and performance assessment as the basis for determining our reportable segments. The performance measures of our reportable segments include net revenues and gross profit.
We have grouped our operations into
two
reportable segments which are also our reporting units: Clear Aligner segment and SCCS segment.
|
•
|
Our Clear Aligner segment consists of our Invisalign system which includes Invisalign Full, Express/Lite, Teen, Assist, Vivera retainers, along with our training and ancillary products for treating malocclusion.
|
|
•
|
Our SCCS segment consists of intra-oral scanning systems and additional services available with the intra-oral scanners that provide digital alternatives to the traditional cast models. This segment includes our iTero scanner and OrthoCAD services.
|
These reportable operating segments are based on how our CODM views and evaluates our operations as well as allocation of resources (in thousands):
|
|
For the Three Months March 31,
|
||||||
|
Revenue
|
2013
|
2012
|
|||||
|
Clear Aligner
|
|||||||
|
Invisalign Full
|
$
|
85,914
|
|
$
|
82,424
|
|
|
|
Invisalign Express/Lite
|
16,083
|
|
11,806
|
|
|||
|
Invisalign Teen
|
18,573
|
|
15,148
|
|
|||
|
Invisalign Assist
|
8,293
|
|
7,193
|
|
|||
|
Invisalign non-case revenues
|
12,709
|
|
6,757
|
|
|||
|
Scanners and CAD/CAM Services
|
|||||||
|
Scanners
|
6,625
|
|
5,361
|
|
|||
|
CAD/CAM Services
|
5,383
|
|
6,390
|
|
|||
|
Total
|
$
|
153,580
|
|
$
|
135,079
|
|
|
|
Gross profit
|
|||||||
|
Clear Aligner
|
$
|
109,327
|
|
$
|
97,389
|
|
|
|
Scanners and CAD/CAM Services
|
3,522
|
|
3,371
|
|
|||
|
Total
|
$
|
112,849
|
|
$
|
100,760
|
|
|
Geographical Information
Net revenues and long-lived assets are presented below by geographic area (in thousands):
|
|
For the Three Months Ended March 31,
|
||||||
|
|
2013
|
2012
|
|||||
|
Net revenues (1):
|
|||||||
|
United States
|
$
|
119,840
|
|
$
|
103,258
|
|
|
|
the Netherlands
|
31,095
|
|
29,447
|
|
|||
|
Other international
|
2,645
|
|
2,374
|
|
|||
|
Total net revenues
|
$
|
153,580
|
|
$
|
135,079
|
|
|
19
|
|
As of March 31,
|
As of December 31,
|
|||||
|
|
2013
|
2012
|
|||||
|
Long-lived assets:
|
|||||||
|
United States
|
$
|
58,898
|
|
$
|
60,098
|
|
|
|
Mexico
|
6,347
|
|
6,473
|
|
|||
|
the Netherlands
|
4,794
|
|
4,707
|
|
|||
|
Other international
|
2,633
|
|
7,913
|
|
|||
|
Total long-lived assets
|
$
|
72,672
|
|
$
|
79,191
|
|
|
_____________
|
(1)
|
Net Revenues are attributed to countries based on location of where revenue is recognized.
|
On April 30, 2013, we acquired ICA Holdings Pty Limited ("ICA") upon the expiration of the term of the distribution agreement between certain subsidiaries of ICA and Align Technology B.V., for a total of approximately
$7.0 million
, which is comprised of
$3.0 million
cash consideration paid on April 30, 2013, and a preliminary estimate of net assets acquired. We expect to complete the acquisition and finalize the purchase price for net assets in the second quarter of 2013.
20
ITEM 2.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
In addition to historical information, this quarterly report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements include, among other things, our expectations regarding the anticipated impact that our new products and product enhancements will have on doctor utilization and our market share, our expectations regarding product mix and product adoption, our expectations regarding the existence and impact of seasonality, our expectations regarding the financial and strategic benefits of the Cadent Holdings, Inc. (“Cadent”) acquisition, our expectations to increase our investment in manufacturing capacity, our expectations regarding the continued expansion of our international markets, the anticipated number of new doctors trained and their impact on volumes, our expectations regarding the International Scanner and CAD/CAM Services revenues, the impact of the termination of our Asia Pacific distributor relationship and reverting to a direct sales model in that region, the level of our operating expenses and gross margins, and other factors beyond our control, as well as other statements regarding our future operations, financial condition and prospects and business strategies. These statements may contain words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” or other words indicating future results. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in Item 2 “Management’s Discussion and Analysis of Financial Condition and Results of Operations”, and in particular, the risks discussed below in Part II, Item 1A “Risk Factors”. We undertake no obligation to revise or update these forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements.
The following discussion and analysis of our financial condition and results of operations should be read together with our Condensed Consolidated Financial Statements and related notes included elsewhere in this Quarterly Report on Form 10-Q.
Overview
Align Technology, Inc. is a global medical device company that pioneered the invisible orthodontics market with the introduction of the Invisalign system in 1999. Today, we are focused on designing, manufacturing and marketing innovative, technology-rich products to help dental professionals achieve the clinical results they expect and deliver effective, convenient cutting-edge dental treatment options to their patients. Align Technology was founded in March 1997 and is headquartered in San Jose, California with offices worldwide. Our international headquarters are located in Amsterdam, the Netherlands. We have two operating segments: (1) Clear Aligner, known as the Invisalign system; and (2) Scanner and CAD/CAM Services ("SCCS"), known as the iTero intra-oral scanners and OrthoCAD services.
We received FDA clearance in 1998 and began our first commercial sales of Invisalign to U.S. Orthodontists in 1999 followed by U.S General Practitioner Dentists (GPs) in 2002. Over the next decade, we introduced Invisalign to the European market and Japan, added distribution partners in Asia-Pacific, Latin America, and EMEA, and introduced a full range of treatment options including Invisalign Express 10, Invisalign Teen, Invisalign Assist, and Vivera retainers. By 2011, we launched Invisalign G3 and Invisalign G4, which include significant new aligner and software features across all Invisalign products that make it easier for doctors to use Invisalign on more complex cases, and introduced Invisalign in the People’s Republic of China. Most recently, we launched SmartTrack, the next generation of Invisalign clear aligner material which became the new standard aligner material for Invisalign clear aligner products in North America and Europe beginning January 21, 2013 and for other international markets where we received regulatory approval.
21
In 2011, we acquired Cadent Holdings, Inc., a leading provider of 3D digital scanning solutions for orthodontics and dentistry, and makers of the iTero intra-oral scanner and OrthoCAD services. We believe that the combination of Align’s and Cadent’s technologies and capabilities creates greater growth opportunities for Align by bringing innovative new Invisalign treatment tools to customers and by extending the value of intra-oral scanning in dental practices. Intra-oral scanners provide a dental “chair-side” platform for accessing valuable digital diagnosis and treatment tools, with potential for enhancing accuracy of records, treatment efficiency, and the overall patient experience. We believe there are numerous benefits for customers and the opportunity to accelerate the adoption of Invisalign through interoperability with our intra-oral scanners. The use of digital technologies such as CAD/CAM for restorative dentistry or in-office restorations has been growing rapidly and intra-oral scanning is a critical part of enabling these new digital technologies and procedures in dental practices. Since the acquisition, we have launched significant product options and software enhancements to the scanner product line. In late 2012, we commercially launched the Invisalign Outcome Simulator, the first Invisalign chair-side application powered by the iTero scanner. The interactive application provides dentists and orthodontists an enhanced platform for patient education and is designed to increase treatment acceptance by helping patients visualize the benefits possible with Invisalign treatment. The new iTero scanner was available in North America beginning in February 2013 and will be available soon thereafter in select international markets as a single hardware platform with software options for restorative or orthodontic procedures.
The Invisalign system is offered in more than 45 countries and has been used to treat more than 2.0 million patients. Our iTero intra-oral scanner is available in over 25 countries and provide dental professionals with an open choice to send digital impressions to any laboratory-based CAD/CAM system or to any of the more than 1,800 dental labs worldwide.
Our goal is to establish the Invisalign system as the standard method for treating malocclusion and to establish our intra-oral scanning platform as the preferred scanning protocol for 3D digital scans, ultimately driving increased product adoption by dental professionals. We intend to achieve this by focusing on the key strategic initiatives set forth in our Annual Report on Form 10-K.
In addition to the successful execution of our business strategy, there are a number of other factors which may affect our results in 2013 and beyond, which are updated below:
|
•
|
Product innovation and clinical effectiveness
. We recently announced the introduction of SmartTrack, a proprietary, custom engineered aligner material, designed to deliver gentle, more constant force to improve control of tooth movements with Invisalign clear aligner treatment will build on the success we have seen with Invisalign G3/G4 and encourage even greater confidence and adoption in our customers’ practices. Although the introduction of SmartTrack will result in higher cost of goods sold and reduction in gross margins in our clear aligner segment in 2013 due to higher material costs, we believe these innovations are important contributors to increase utilization across our channels worldwide. Additionally, we recently introduced the new iTero scanner, which is a single hardware platform with software options for restorative or orthodontic procedures, Invisalign interoperability, as well as the Invisalign Outcome Simulator, our first chair-side application powered by our iTero scanner. We believe that over the long-term these types of product and clinical innovations will increase adoption of Invisalign and increase sales of our intra-oral scanners. However, it is difficult to predict the rate of adoption, which may vary by region and channel.
|
|
•
|
Invisalign Utilization rates.
Our goal is to establish Invisalign as the treatment of choice for treating malocclusion ultimately driving increased product adoption and frequency of use by dental professionals, or utilization. Our quarterly utilization rates for the previous 9 quarters are as follows:
|
22
__________________
*Invisalign Utilization rates = # of cases shipped divided by # of doctors cases were shipped to
Total utilization in the first quarter of 2013 increased slightly to 4.3 cases per doctor compared to 4.1 cases in the first quarter of 2012 driven primarily by North American Orthodontists. Utilization among our North American orthodontist customers increased from 7.2 in the first quarter of 2012 to 8.0 cases per doctor, reflecting continued adoption of our Invisalign products driven by ongoing product improvements and feature launches. Utilization among our North American General Practitioner ("GP") and International doctors increased slightly. As doctors increase their utilization, we anticipate higher participation in our volume rebate program which may result in lower average selling prices of our products.
|
•
|
Number of new Invisalign doctors trained.
We continue to expand our Invisalign customer base by training new doctors. In 2012, Invisalign growth was driven primarily by the continued expansion of our customer base as we trained a total of 6,845 new orthodontists and GPs in North America and internationally. We expect to train approximately 7,220 doctors in 2013. In the first quarter of 2013, we trained a total of 1,660 new Invisalign doctors, adding 65 North American Orthodontists, 690 North American GPs and 905 International doctors.
|
|
•
|
International Clear Aligner.
We will continue to focus our efforts towards increasing adoption of our products by dental professionals in our core European markets as well as expanding into new markets. On a year over year basis, international volume increased 17% compared to the first quarter of 2012, reflecting growth in our direct business in Europe as well as by our distribution partners. Based on the continued progress in the Asia-Pacific region, we did not renew our distribution agreement for this region when it expired on April 30, 2013, and we transitioned back to a direct sales model on May 1, 2013. Now four of the largest indirect country markets of Australia, New Zealand, Hong Kong and Singapore are direct sales regions and we began to recognize direct sales of Invisalign products sold in that region at our full average selling price ("ASP") rather than at the discounted average sales price under the distribution agreement. In 2012, this distributor accounted for approximately 3% of worldwide revenues, and we expect them to become an even more meaningful contributor to revenue growth in 2013. In the near term, however, the assumption of the direct operating costs will offset the uplift to ASPs. Although we expect volumes and revenues will increase, we may experience difficulties in achieving the anticipated financial benefits. We expect the remaining eight indirect country markets in Brunei, Indonesia, Macau, Malaysia, Philippines, South Korea, Taiwan, Thailand and Vietnam as well as the EMEA and Latin America regions will continue under a distribution model.
|
23
|
•
|
Increased Sales Force Coverage.
Our direct sales organization in North America is comprised of a team of territory managers and to a lesser extent, territory specialists. These territory specialists are used to enhance coverage in larger territories, especially with our lower volume GP customers. Due to the success of this sales coverage model, we expect to add approximately 20 sales representatives in 2013, predominantly in North America. In addition, with the transition of our Asia-Pacific distributor to a direct sales model in May 2013, we acquired approximately 15 additional sales representatives in that region.
|
|
•
|
Vivera Retainer Shipment Consolidation in North America.
In the first quarter of 2013, we began consolidating Vivera retainer product shipments into one shipment per year rather than four shipments per year as had been our practice. As a result, our first quarter results reflected approximately $4.4 million benefit to revenue associated with our Vivera product as we recognized nine additional months of the subscription revenue in the first quarter instead of recognizing it ratably every quarter for one year. In addition, we will also begin to reduce freight costs as we make this change.
|
|
•
|
Change to Mid-Course Correction Policy.
We seek to continually evaluate and improve our products, our customer support processes and policies to support those goals. Based on customer feedback, beginning June 15, 2013, we will no longer charge a fee associated with our mid-course correction orders. Mid-course correction provides our customers with the option of requesting a treatment correction during active treatment if the case is not tracking to the original treatment plan or goals. Beginning June 15, 2013, we will include up to three mid-course correction orders per case free of charge in our list prices for Invisalign Full and Invisalign Teen. As a result of this change, Invisalign clear aligner revenues for the first quarter of 2013 were decreased by $2.7 million, representing the revenue deferred to provide free mid-course corrections for open cases that we expect to be eligible when this new policy takes effect. Based on an historical usage rate, we will defer approximately $10 per case, which will be recognized when mid-course corrections orders are shipped. In addition, because we will no longer charge and bill customers for mid-course correction orders, we anticipate a reduction of revenues of approximately $700,000 per quarter.
|
|
•
|
International Scanner and CAD/CAM Services.
In October 2012, we reached a mutual agreement to terminate the exclusive distribution arrangement with Straumann for iTero intra-oral scanners in Europe, as well as the non-exclusive distribution agreement for iTero intra-oral scanners in North America effective December 31, 2012. The global market for restorative dentistry is far more fragmented and complex than for orthodontics, involving hundreds of thousands of labs, suppliers, general dentists and specialists. In Europe, adoption of digital restorative technology has been slowed due to challenging economic conditions and reluctance to invest in capital equipment. In view of these conditions, we expect to have very few scanner sales internationally in the near term as we determine the most effective way to re-stage growth in this market. Our direct sales model remains unchanged in North America where most of the scanner and CAD/CAM services revenue is generated.
|
|
•
|
Increase in Invisalign Selling Price
. In recent years, we have significantly increased investment in research and development resulting in product innovations, such as Invisalign G3, Invisalign G4 and SmartTrack clear aligner material. We have also continued to increase our consumer advertising spending to drive more patient demand. In addition, beginning January 1, 2013, the Federal Government imposed a new excise tax on medical device manufacturers, and Invisalign clear aligners are considered a taxable medical device. As a result of this new tax and our continued investments in research and development and consumer advertising, we increased our Invisalign pricing by adding $26.00 to $50.00 per case compared to 2012 prices, effective January 1, 2013. For 2013, we expect that the impact on our average sales price from this price increase will be offset somewhat by an expected increases in our rebate program due to the anticipated increase in utilization by our customers, increased volume from our lower price products, including Invisalign Express 5 and Invisalign i7, as well as slightly higher material costs for the SmartTrack clear aligner material. The prices for Invisalign Teen, Invisalign retainers and Vivera retainers will remain unchanged.
|
|
•
|
2013 Operating expenses.
We expect operating expenses to increase in 2013 compared to 2012 due to the increase in North American sales force coverage, the acquisition of the direct sales force in Asia-Pacific, and the inclusion of the medical device excise tax, which was enacted into law as part of the comprehensive healthcare reform legislation in March 2010.
|
24
|
•
|
Foreign exchange rates.
Although the U.S. dollar is our reporting currency, a portion of our net revenues and income are generated in foreign currencies. Net revenues and income generated by subsidiaries operating outside of the U.S. are translated into U.S. dollars using exchange rates effective during the respective period and as a result are affected by changes in exchange rates. We have generally accepted the exposure to exchange rate movements without using derivative financial instruments to manage this risk. Therefore, both positive and negative movements in currency exchange rates against the U.S. dollar will continue to affect the reported amount of net revenues and income in our consolidated financial statements.
|
|
•
|
Goodwill and Long Lived Asset Impairments.
Recent changes in the competitive environment, including announcements in March 2013 of new lower-priced scanners targeted at Orthodontists and GPs in North America caused us to lower our expectations for growth and profitability for our scanner and CAD/CAM services business. As a result, we conducted an impairment analysis of long-lived assets and goodwill related to the SCCS reporting unit. Based on these analyses, we recorded a $26.3 million impairment of our long-lived assets and $40.7 million impairment of goodwill. The $40.7 million represents the remaining goodwill balance in the SCCS reporting unit. More information regarding the impairment of our goodwill and long lived assets, including a description of steps one and two of the analysis, and the approaches taken in the analysis of goodwill, can be found in Note 4 of the Condensed Consolidated Financial Statements included in Part I of this Form 10-Q.
|
|
•
|
Acquired Intangible Asset Amortization.
The total impairment charge of our long-lived assets of $26.3 million consisted of $19.3 million of impairment related to our acquired SCCS intangible assets and $7.0 million related to plant and equipment. Prior to impairment, the quarterly amortization expense of acquired intangible assets was approximately $1.1 million. Going forward, the amortization expense of acquired intangible assets will be around $0.7 million per quarter. More information regarding estimated annual future amortization expense for these acquired intangible assets can be found in Note 4 of the Condensed Consolidated Financial Statements included in Part I of this Form 10-Q.
|
Results of Operations
Net revenues by Reportable Segment
We group our operations into two reportable segments: Clear Aligner segment and Scanners and CAD/CAM Services segment.
|
•
|
Our Clear Aligner segment consists of our Invisalign system which includes Invisalign Full, Express/Lite, Teen, Assist, Vivera retainers, along with our training and ancillary products for treating malocclusion.
|
|
•
|
Our Scanners and CAD/CAM Services segment consists of intra-oral scanning systems and additional services available with the intra-oral scanners that provide digital alternatives to the traditional cast models. This segment includes our iTero scanners, iOC scanners, and OrthoCAD services.
|
25
The below represents net revenues for our Clear Aligner segment by region, channel, and product and our Scanner and CAD/CAM Services segment by region and product for the three months ended March 31, 2013 and 2012 as follows (in millions):
|
|
Three Months Ended March 31,
|
|||||||||||||
|
Clear Aligner:
|
2013
|
2012
|
Net
Change
|
%
Change
|
||||||||||
|
Region and Channel
|
||||||||||||||
|
North America
|
||||||||||||||
|
Ortho
|
$
|
48.9
|
|
$
|
41.7
|
|
$
|
7.2
|
|
17.3
|
%
|
|||
|
GP
|
48.2
|
|
45.2
|
|
3.0
|
|
6.6
|
%
|
||||||
|
Total North America
|
97.1
|
|
86.9
|
|
10.2
|
|
11.7
|
%
|
||||||
|
International
|
31.8
|
|
29.6
|
|
2.2
|
|
7.4
|
%
|
||||||
|
Invisalign non-case revenues
|
12.7
|
|
6.8
|
|
5.9
|
|
86.8
|
%
|
||||||
|
Total
|
$
|
141.6
|
|
$
|
123.3
|
|
$
|
18.3
|
|
14.8
|
%
|
|||
|
Product
|
||||||||||||||
|
Invisalign Full
|
$
|
85.9
|
|
$
|
82.4
|
|
$
|
3.5
|
|
4.2
|
%
|
|||
|
Invisalign Express/Lite
|
16.1
|
|
11.8
|
|
4.3
|
|
36.4
|
%
|
||||||
|
Invisalign Teen
|
18.6
|
|
15.1
|
|
3.5
|
|
23.2
|
%
|
||||||
|
Invisalign Assist
|
8.3
|
|
7.2
|
|
1.1
|
|
15.3
|
%
|
||||||
|
Invisalign non-case revenues
|
12.7
|
|
6.8
|
|
5.9
|
|
86.8
|
%
|
||||||
|
Total
|
$
|
141.6
|
|
$
|
123.3
|
|
$
|
18.3
|
|
14.8
|
%
|
|||
|
Scanners and CAD/CAM Services:
|
||||||||||||||
|
Region
|
||||||||||||||
|
North America
|
$
|
11.5
|
|
$
|
11.1
|
|
$
|
0.4
|
|
3.6
|
%
|
|||
|
International
|
0.5
|
|
0.7
|
|
(0.2
|
)
|
(28.6
|
)%
|
||||||
|
Total
|
$
|
12.0
|
|
$
|
11.8
|
|
$
|
0.2
|
|
1.7
|
%
|
|||
|
Product
|
||||||||||||||
|
Scanners
|
$
|
6.6
|
|
$
|
5.4
|
|
$
|
1.2
|
|
22.2
|
%
|
|||
|
CAD/CAM Services
|
5.4
|
|
6.4
|
|
(1.0
|
)
|
(15.6
|
)%
|
||||||
|
Total
|
$
|
12.0
|
|
$
|
11.8
|
|
$
|
0.2
|
|
1.7
|
%
|
|||
|
Total Revenue
|
$
|
153.6
|
|
$
|
135.1
|
|
$
|
18.5
|
|
13.7
|
%
|
|||
Clear Aligner Case Volume by Channel and Product
26
Case volume data which represents Invisalign case shipments by channel and product, for the three months ended March 31, 2013 and 2012 is as follows (in thousands):
|
|
Three Months Ended March 31,
|
||||||||||
|
Region and Channel
|
2013
|
2012
|
Net
Change
|
%
Change
|
|||||||
|
North America:
|
|||||||||||
|
Ortho
|
38.0
|
|
32.3
|
|
5.7
|
|
17.6
|
%
|
|||
|
GP
|
36.7
|
|
33.0
|
|
3.7
|
|
11.2
|
%
|
|||
|
Total North American Invisalign
|
74.7
|
|
65.3
|
|
9.4
|
|
14.4
|
%
|
|||
|
International Invisalign
|
23.5
|
|
20.0
|
|
3.5
|
|
17.5
|
%
|
|||
|
Total Invisalign case volume
|
98.2
|
|
85.3
|
|
12.9
|
|
15.1
|
%
|
|||
|
Product
|
|||||||||||
|
Invisalign Full
|
61.3
|
|
57.2
|
|
4.1
|
|
7.2
|
%
|
|||
|
Invisalign Express/Lite
|
18.9
|
|
12.9
|
|
6.0
|
|
46.5
|
%
|
|||
|
Invisalign Teen
|
12.6
|
|
9.9
|
|
2.7
|
|
27.3
|
%
|
|||
|
Invisalign Assist
|
5.4
|
|
5.3
|
|
0.1
|
|
1.9
|
%
|
|||
|
Total Invisalign case volume
|
98.2
|
|
85.3
|
|
12.9
|
|
15.1
|
%
|
|||
Total net revenues increased by $18.5 million for the three months ended March 31, 2013 as compared to the same period in 2012 primarily as a result of worldwide volume growth across all Clear Aligner customer channels and products and an increase in Invisalign non-case revenue.
Clear Aligner
In the three months ended March 31, 2013, Clear Aligner North America net revenues increased by 11.7% compared to the same period in 2012. The growth was primarily driven by volume growth across all products and customer channels partially offset by lower ASPs, largely as a result of a product mix shift towards lower priced Express products and a revenue deferral to provide for free mid-course correction for open cases that we expect to be eligible when this new policy takes effect in June 2013.
In the three months ended March 31, 2013, Clear Aligner International net revenues increased by 7.4% compared to the same period in 2012, driven primarily by volume growth across all products, partially offset by lower ASPs due to an increase in discounts, distributor mix and a product mix shift towards lower priced Lite products.
Other non-case revenues, consisting of training fees and sales of ancillary products, increased 86.6% for the three months ended March 31, 2013 compared to the same period in 2012 primarily due to the consolidation of Vivera from four shipments per year down to one shipment per year in North America.
Scanner and CAD/CAM Services
SCCS revenue remained consistent for the three months ended March 31, 2013 compared to the same period in 2012. The scanner revenue increased for the three months ended March 31, 2013 primarily due to the release of revenue previously reserved for the new iTero scanner upgrade program, which was available through the end of the first quarter. CAD/CAM Services decreased for the three months ended March 31, 2013 primarily due to the discontinuation of OrthoCAD iQ services during the fourth quarter of 2012.
Cost of net revenues and gross profit (in millions):
27
|
|
Three Months Ended March 31,
|
||||||||||
|
|
2013
|
2012
|
Change
|
||||||||
|
Clear Aligner
|
|||||||||||
|
Cost of net revenues
|
$
|
32.2
|
|
$
|
25.9
|
|
$
|
6.3
|
|
||
|
% of net segment revenues
|
22.8
|
%
|
21.0
|
%
|
|||||||
|
Gross profit
|
$
|
109.3
|
|
$
|
97.4
|
|
$
|
11.9
|
|
||
|
Gross margin %
|
77.2
|
%
|
79.0
|
%
|
|||||||
|
Scanner and CAD/CAM Services
|
|||||||||||
|
Cost of net revenues
|
$
|
8.5
|
|
$
|
8.4
|
|
$
|
0.1
|
|
||
|
% of net segment revenues
|
70.7
|
%
|
71.3
|
%
|
|||||||
|
Gross profit
|
$
|
3.5
|
|
$
|
3.4
|
|
$
|
0.1
|
|
||
|
Gross margin %
|
29.3
|
%
|
28.7
|
%
|
|||||||
|
Total cost of net revenues
|
$
|
40.7
|
|
$
|
34.3
|
|
$
|
6.4
|
|
||
|
% of net revenues
|
26.5
|
%
|
25.4
|
%
|
|||||||
|
Gross profit
|
$
|
112.9
|
|
$
|
100.8
|
|
$
|
12.1
|
|
||
|
Gross margin %
|
73.5
|
%
|
74.6
|
%
|
|||||||
Cost of net revenues for our Clear Aligner and SCCS includes salaries for staff involved in the production process, the cost of materials, packaging, shipping costs, depreciation on capital equipment used in the production process, amortization of acquired intangible assets from Cadent, training costs and stock-based compensation expense.
Clear Aligner
Gross margin decreased slightly for the three months ended
March 31, 2013
compared to the same period in 2012 reflecting higher inventory reserves and lower ASPs. The additional inventory reserve was for the prior aligner material as we transitioned to our new SmartTrack material in February 2013.
Scanner and CAD/CAM Services
Gross margin increased for the three months ended
March 31, 2013
compared to the same period in 2012 largely due to the release of revenue previously reserved for the new iTero scanner upgrade program. This was partially offset by unabsorbed manufacturing spend due to lower production volumes and increased warranty cost.
Sales and marketing (in millions):
|
|
Three Months Ended March 31,
|
||||||||||
|
|
2013
|
2012
|
Change
|
||||||||
|
Sales and marketing
|
$
|
42.3
|
|
$
|
38.7
|
|
$
|
3.6
|
|
||
|
% of net revenues
|
27.5
|
%
|
28.7
|
%
|
|||||||
Sales and marketing expense includes sales force and marketing compensation (including travel-related costs), media and advertising, clinical education, expenses for trade shows and industry events, product marketing and stock-based compensation expense.
Our sales and marketing expense for the three months ended
March 31, 2013
increased compared to the same period in 2012 primarily due to higher advertising, product marketing, and sales event costs of approximately $3.0 million. We also incurred additional transition costs of approximately $1.0 million related to the conversion of our Asia-Pacific distributor back into a direct sales model effective on May 1, 2013. These costs were partially offset by lower media spend of approximately $0.4 million.
General and administrative (in millions):
28
|
|
Three Months Ended March 31,
|
||||||||||
|
|
2013
|
2012
|
Change
|
||||||||
|
General and administrative
|
$
|
30.3
|
|
$
|
23.5
|
|
$
|
6.8
|
|
||
|
% of net revenues
|
19.8
|
%
|
17.4
|
%
|
|||||||
General and administrative expense includes salaries for administrative personnel, outside consulting services, legal expenses and stock-based compensation expense.
General and administrative expense increased for the three months ended
March 31, 2013
compared to the same period in 2012 largely due to higher payroll expense of $3.0 million resulting from annual compensation adjustments and an increase in headcount; higher legal fees of approximately $2.4 million; and a $1.5 million increase in Medical Device Excise Tax.
Research and development (in millions):
|
|
Three Months Ended March 31,
|
||||||||||
|
|
2013
|
2012
|
Change
|
||||||||
|
Research and development
|
$
|
11.3
|
|
$
|
10.5
|
|
$
|
0.8
|
|
||
|
% of net revenues
|
7.3
|
%
|
7.8
|
%
|
|||||||
Research and development expense includes the personnel-related costs and outside consulting expenses associated with the research and development of new products and enhancements to existing products, corporate allocations, facility and facility related costs and stock-based compensation expense.
Research and development expense increased during the three months ended
March 31, 2013
, compared to the same period in 2012 mostly due to higher payroll costs of approximately $0.6 million resulting from annual compensation adjustments as well as higher headcount, outside consulting, facility, and depreciation related expenses of approximately $0.2 million.
Impairment of goodwill (in millions):
|
|
Three Months Ended March 31,
|
||||||||||
|
|
2013
|
2012
|
Change
|
||||||||
|
Impairment of goodwill
|
$
|
40.7
|
|
$
|
—
|
|
$
|
40.7
|
|
||
|
% of net revenues
|
26.5
|
%
|
—
|
%
|
|||||||
During the first quarter of 2013, we determined that the goodwill for our SCCS reporting unit should be tested for impairment between annual tests since an event occurred or circumstances changed that would more likely than not reduce the fair value of our SCCS reporting unit below its carrying amount. As a result of our analysis, we recorded goodwill impairment charge during of $40.7 million. None of the goodwill impairment charge was deductible for tax purposes. Refer to Note 4 for details of the impairment analysis.
Impairment of long-lived assets (in millions):
|
|
Three Months Ended March 31,
|
||||||||||
|
|
2013
|
2012
|
Change
|
||||||||
|
Impairment of long-lived assets
|
$
|
26.3
|
|
$
|
—
|
|
$
|
26.3
|
|
||
|
% of net revenues
|
17.1
|
%
|
—
|
%
|
|||||||
The impairment of our long-lived assets was the result of changes in the competitive environment for intra-oral scanners which included announcements of new low-priced scanners targeted at Orthodontist and GP Dentist in North America that caused us to lower our expectations for growth and profitability for our SCCS reporting unit. As a result, we determined that the carrying value of the long-lived assets was not recoverable and therefore recorded an impairment charge of $26.3 million. Refer to Note 4 for details of the impairment analysis.
29
Interest and other income (expense), net (in millions):
|
|
Three Months Ended March 31,
|
||||||||||
|
|
2013
|
2012
|
Change
|
||||||||
|
Interest income
|
$
|
0.2
|
|
$
|
0.2
|
|
$
|
—
|
|
||
|
Other expense, net
|
(1.2
|
)
|
(1.0
|
)
|
(0.2
|
)
|
|||||
|
Total interest income and other expense, net
|
$
|
(1.0
|
)
|
$
|
(0.8
|
)
|
$
|
(0.2
|
)
|
||
Interest and other income (expense), net, includes interest income earned on cash and investment balances, foreign currency translation gains and losses, and other miscellaneous charges.
Interest income for the three months ended
March 31, 2013
were relatively consistent compared to the same periods in 2012. Other expense for the three months ended
March 31, 2013
compared to the same periods in 2012 increased reflecting higher foreign exchange losses.
Income tax (in millions):
|
|
Three Months Ended March 31,
|
||||||||||
|
|
2013
|
2012
|
Change
|
||||||||
|
Provision for income taxes
|
$
|
2.9
|
|
$
|
6.2
|
|
$
|
(3.3
|
)
|
||
|
Effective tax rates
|
(7.5
|
)%
|
22.8
|
%
|
|||||||
For the three months ended March 31, 2013 and 2012, the Company's tax expense was $2.9 million and $6.2 million, respectively, representing effective tax rates of (7.5%) and 22.8%. The effective tax rate decreased primarily due to a jurisdictional shift in forecasted earnings from the U.S. to lower-tax non-U.S. jurisdictions, as well as the impact of the impairment of goodwill and long-lived assets for the three months ended March 31, 2013.
The Company's tax expense of $2.9 million for the three months ended March 31, 2013 is comprised primarily of a benefit related to a pre-tax loss for the period offset by income tax expense of $5.8 million related to the impairment of goodwill and long-lived assets. The $5.8 million is comprised of a $9.7 million tax expense due to a non-deductible goodwill impairment charge offset by a $3.9 million tax benefit associated with the impairment of long-lived assets.
On January 2, 2013, the American Taxpayer Relief Act of 2012 (H.R. 8, as amended) was signed into law. This Act extends the federal research and development credit through December 31, 2013. The federal research and development credit was reinstated retroactively to January 1, 2012. The tax benefit of the federal research and development credit for the twelve months ended December 31, 2012 resulted in a discrete tax benefit of $0.5 million in the first quarter of fiscal year 2013, the period in which the reinstatement was enacted into law.
We exercise significant judgment in regards to estimates of future market growth, forecasted earnings and projected taxable income, in determining the provision for income taxes, and for purposes of assessing our ability to utilize any future benefit from deferred tax assets.
As of
March 31, 2013
, we maintain a valuation allowance of $30.0 million against deferred tax assets primarily related to foreign net operating loss carryforwards. These net operating loss carryovers would result in an income tax benefit if we were to conclude it is more likely than not that the related deferred tax assets will be realized.
During the first quarter of fiscal year 2013, the amount of gross unrecognized tax benefits increased by approximately $1.4 million primarily due to current period exposures. The total amount of gross unrecognized tax benefits was $22.1 million as of March 31, 2013, all of which would impact our effective tax rate if realized. We have elected to recognize interest and penalties related to unrecognized tax benefits as a component of income taxes. The change in accrued interest and penalties during the first quarter of fiscal year 2013 was not material. We do not expect any significant changes to the amount of unrecognized tax benefit within the next twelve months.
We are subject to taxation in the U.S., and various states and foreign jurisdictions. All of our tax years will be open to examination by the U.S. federal and most state tax authorities due to our net operating loss and overall credit carryforward
30
position. With few exceptions, we are no longer subject to examination by foreign tax authorities for years before 2006. Our subsidiaries in Israel and Germany are under audit by the local tax authorities for calendar years 2006 through 2011 and 2007 through 2011, respectively.
Revision of Prior Period Financial Statements
In connection with the preparation of our consolidated financial statements for the third quarter of 2012, we determined that we had not correctly recognized the excess tax benefits related to stock-based awards in the first quarter of 2012.
In accordance with Staff Accounting Bulletin (SAB) No. 99, “Materiality”, and SAB No. 108, “Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements”, we evaluated the materiality of the errors from qualitative and quantitative perspectives, and evaluated the quantified errors under both the iron curtain and the roll-over methods. We concluded that the errors were not material to the financial statements for the first quarter of 2012 and revised the presentation of the statement of cash flows for the first quarter of 2012.
The following tables summarize the effects of the revision on our Condensed Consolidated Statement of Cash Flows. The revision did not impact our Condensed Consolidated Statement of Operations for the first quarter of 2012.
Cash flows
|
Three Months Ended March 31, 2012
|
|||||||||||
|
(in thousands)
|
|||||||||||
|
Previously Reported
|
Adjustment
|
As Revised
|
|||||||||
|
Statement of Cash Flows
|
|||||||||||
|
Net cash provided by operating activities
|
$
|
15,424
|
|
$
|
(8,043
|
)
|
$
|
7,381
|
|
||
|
Net cash provided by financing activities
|
6,248
|
|
8,043
|
|
14,291
|
|
|||||
|
Net decrease in cash and cash equivalents
|
(16,314
|
)
|
—
|
|
(16,314
|
)
|
|||||
Liquidity and Capital Resources
We fund our operations from product sales and the proceeds from the sale of our common stock. As of
March 31, 2013
and
December 31, 2012
, we had the following cash and cash equivalents, and short-term and long-term investments (in thousands):
|
March 31 ,
2013
|
December 31,
2012
|
||||||
|
Cash and cash equivalents
|
$
|
328,745
|
|
$
|
306,386
|
|
|
|
Marketable securities, short-term
|
37,975
|
|
28,485
|
|
|||
|
Marketable securities, long-term
|
10,680
|
|
21,252
|
|
|||
|
Total
|
$
|
377,400
|
|
$
|
356,123
|
|
|
Cash flows
(in thousands):
|
|
Three Months Ended March 31,
|
|||||||
|
|
2013
|
2012 (revised)
|
||||||
|
Net cash flow provided by (used in) :
|
||||||||
|
Operating activities
|
$
|
10,418
|
|
$
|
7,381
|
|
||
|
Investing activities
|
(3,445
|
)
|
(37,995
|
)
|
||||
|
Financing activities
|
15,423
|
|
14,291
|
|
||||
|
Effects of exchange rate changes on cash and cash equivalents
|
(37
|
)
|
9
|
|
||||
|
Net increase (decrease) in cash and cash equivalents
|
$
|
22,359
|
|
$
|
(16,314
|
)
|
||
As of
March 31, 2013
we had $328.7 million of cash, cash equivalents, and marketable securities. Cash equivalents and marketable securities are comprised of money market funds and debt instruments which include commercial paper, corporate bonds, and foreign bonds.
31
As of
March 31, 2013
, approximately $152.4 million of cash and cash equivalents was held by our foreign subsidiaries. Amounts held by foreign subsidiaries are generally subject to U.S. income taxation on repatriation to the U.S. Such earnings that
are intended to be permanently reinvested outside of the U.S. are not subject to U.S. income taxation.
Operating Activities
For the three months ended
March 31, 2013
, cash flows from operations of
$10.4 million
resulted primarily from our net loss of approximately $42.0 million and the following reasons:
Non-cash activities
|
•
|
Impairment of goodwill was $40.7 million.
|
|
•
|
Impairment of Long Lived Assets was $26.3 million.
|
|
•
|
Excess tax benefits from our share-based payments were $7.7 million.
|
|
•
|
Stock-based compensation expense was $6.4 million related to equity incentive compensation granted to employees.
|
|
•
|
Depreciation, amortization, and the amortization of intangibles were $5.0 million including the impact of the acquired assets and intangible assets resulting from the Cadent acquisition as well as the additional fixed assets that were placed into service in our new Juarez facility during the first half of 2012.
|
|
•
|
Recovery of allowance for doubtful accounts and returns were $1.2 million.
|
|
•
|
Release of Deferred taxes were $0.9 million primarily due to the utilization of our deferred tax assets.
|
Changes in working capital
|
•
|
Accounts receivable increased by $9.2 million due to the increase in net revenues during the first quarter of 2013. reducing our cash inflow from operations.
|
|
•
|
Prepaid expenses and other assets increased $0.6 million primarily due to the timing of sales and marketing events, reducing our cash inflow from operations.
|
|
•
|
Accounts payable increased by $1.6 million during the first quarter of 2013, increasing our cash inflow from operating activities.
|
|
•
|
Accrued and other long-term liabilities decreased by $7.9 million primarily due to the payments of our incentive compensation during the first quarter of 2013, reducing our cash inflow from operating activities.
|
|
•
|
Deferred revenues decreased by $1.5 million primarily due to the release of revenue previously reserved for the new iTero scanner upgrade program during the first quarter of 2013, decreasing our cash inflow from operating activities.
|
For the three months ended March 31, 2012, cash flows from operations of approximately $7.3 million resulted primarily from our net income of approximately $21.0 million and the following reasons:
Changes in non-cash activities
|
•
|
Excess tax benefits from our share-based payments were $8.0 million.
|
|
•
|
Deferred taxes were approximately $4.7 million primarily due to the utilization of our deferred tax assets.
|
|
•
|
Depreciation, amortization, and the amortization of intangibles were approximately $3.9 million including the impact of the acquired assets and intangible assets resulting from the Cadent acquisition as well as the additional fixed assets that were placed into service in our new Juarez facility during the quarter.
|
|
•
|
Stock-based compensation expense was approximately $4.9 million related to equity incentive compensation granted to employees.
|
|
•
|
Other non-cash activities including the recovery from doubtful accounts and the loss on the retirement/disposal of our fixed assets of $0.1 million.
|
32
Changes in working capital
|
•
|
Accrued and other long-term liabilities decreased by $9.2 million primarily due to the payments of our annual incentive compensation, commission-related costs and sales rebate costs, reducing our cash inflow from operating activities.
|
|
•
|
Inventories increased by $4.0 million which was primarily due to increased purchases of raw materials purchased for our intra-oral scanner products as we increased production volumes in preparation for the move into our new facility in Israel, reducing our cash inflow from operating activities.
|
|
•
|
Accounts receivable increased by $2.4 million due to the increase in net revenues during the first quarter, reducing our cash inflow from operating activities.
|
|
•
|
Accounts payable decreased by $3.6 million during the first quarter, reducing our cash inflow from operating activities.
|
|
•
|
Prepaid expenses and other assets increased $1.5 million primarily due to the timing of software license and insurance policy renewals, reducing our cash inflow from operations.
|
|
•
|
Deferred revenues increased by $1.8 million primarily due to higher sales during the first quarter, increasing our cash inflow from operating activities.
|
Investing Activities
Net cash used in investing activities was $3.4 million for the three months ended
March 31, 2013
primarily consisted of our purchase of property and equipment of $5.6 million and marketable securities of $3.3 million. These costs were partially offset by $4.4 million of maturities of our marketable securities and the release of $1.1 million of funds we hold related to unclaimed merger consideration for the acquisition of Cadent on April 29, 2011.
Net cash used in investing activities was $38.0 million for the three months ended March 31, 2012 primarily consisted of purchase of marketable securities of 28.2 million and property and equipment purchases of $12.6 million. These costs were partially offset by $2.8 million of maturities of our marketable securities.
Although we believe our current investment portfolio has little risk of impairment, we cannot predict future market conditions or market liquidity and can provide no assurance that our investment portfolio will remain unimpaired.
Financing Activities
Net cash provided by financing activities was
$15.4 million
for the three months ended
March 31, 2013
primarily resulting from $13.3 million in proceeds from the issuance of our common stock and $7.7 million from excess tax benefit from our share-based payment arrangements. These were partially offset by $2.4 million of common stock repurchases and $3.1 million of taxes paid for our employees' vesting of restricted stock units.
Net cash provided by financing activities was $14.3 million for the three months ended March 31, 2012 primarily resulting in $10.2 million in proceeds from the issuance of our common stock and $8.0 million from excess tax benefit from our share-based payment arrangements, which were partially offset by $2.5 million of common stock repurchases and $1.4 million of taxes paid for our employees' vesting of restricted stock units.
Stock Repurchase
On October 27, 2011, we announced that our Board of Directors approved a stock repurchase program pursuant to which we may repurchase up to
$150.0 million
of common stock subject to market conditions, share price and other considerations. Purchases under the stock repurchase program may be made from time to time in the open market. As of
March 31, 2013
, there remains approximately
$92.6 million
available under our existing stock repurchase authorization.
33
Contractual Obligations
We believe that our current cash and cash equivalents combined with our existing borrowing capacity will be sufficient to fund our operations for at least the next 12 months. If we are unable to generate adequate operating cash flows, we may need to seek additional sources of capital through equity or debt financing, collaborative or other arrangements with other companies, bank financing and other sources in order to realize our objectives and to continue our operations. There can be no assurance that we will be able to obtain additional debt or equity financing on terms acceptable to us, or at all. If adequate funds are not available, we may need to make business decisions that could adversely affect our operating results such as modifications to our pricing policy, business structure or operations. Accordingly, the failure to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on our business, results of operations and financial condition.
Off-Balance Sheet Arrangements
As of March 31, 2013, we had no off-balance sheet arrangements that have, or are reasonably likely to have, a current or future material effect on our consolidated financial condition, results of operations, liquidity, capital expenditures or capital resources.
Indemnification Provisions
In the normal course of business to facilitate transactions in our services and products, we indemnify certain parties: customers, vendors, lessors, and other parties with respect to certain matters, including, but not limited to, services to be provided by us and intellectual property infringement claims made by third parties. In addition, we have entered into indemnification agreements with our directors and certain of our officers that will require us, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. Several of these agreements limit the time within which an indemnification claim can be made and the amount of the claim.
It is not possible to make a reasonable estimate of the maximum potential amount under these indemnification agreements due to the unique facts and circumstances involved in each particular agreement. Additionally, we have a limited history of prior indemnification claims and the payments we have made under such agreements have not had a material adverse effect on our results of operations, cash flows, or financial position. However, to the extent that valid indemnification claims arise in the future, future payments by us could be significant and could have a material adverse effect on our results of operations or cash flows in a particular period. As of March 31, 2013, we did not have any material indemnification claims that were probable or reasonably possible.
Critical Accounting Policies and Estimates
Management’s discussion and analysis of our financial condition and results of operations is based upon our Condensed Consolidated Financial Statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of condensed consolidated financial statements requires our management to make estimates and judgments that affect the reported amounts of assets and liabilities, net revenues and expenses and disclosures at the date of the financial statements. We evaluate our estimates on an on-going basis, including those related to revenue recognition, accounts receivable, intangible assets, legal contingencies, impairment of goodwill and income taxes. We use authoritative pronouncements, historical experience and other assumptions as the basis for making estimates. Actual results could differ from those estimates.
We believe the following critical accounting policies reflect our most significant estimates, judgments and assumptions used in the preparation of our consolidated financial statements. These critical accounting policies and related disclosures appear in our Annual Report on Form 10-K for the year ended December 31, 2012.
|
•
|
Revenue recognition;
|
|
•
|
Stock-based compensation expense;
|
|
•
|
Long-lived assets, including finite-lived purchased intangible assets;
|
|
•
|
Deferred tax valuation allowance;
|
|
•
|
Goodwill; and
|
|
•
|
Impairment of goodwill and long-lived assets
|
34
Recent Accounting Pronouncements
See Note 1 “Summary of Significant Accounting Policies” of the Notes to Condensed Consolidated Financial Statements for a discussion of recent accounting pronouncements.
ITEM 3.
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
For quantitative and qualitative disclosures about market risk affecting us, see Item 7A, “Quantitative and Qualitative Disclosures About Market Risk,” in our Annual Report on Form 10-K for the year ended December 31, 2012, which is incorporated herein by reference. Our exposure to market risk has not changed materially since December 31, 2012.
ITEM 4.
CONTROLS AND PROCEDURES
Evaluation of disclosure controls and procedures.
Under the supervision and with the participation of our management, including our Chief Executive Officer and our Chief Financial Officer, we have evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based upon that evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures are effective as of
March 31, 2013
, to provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and our Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure, and that such information is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms.
Changes in internal control over financial reporting.
There were no changes in our internal control over financial reporting that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
35
Securities Class Action Lawsuit
On November 28, 2012, plaintiff City of Dearborn Heights Act 345 Police & Fire Retirement System filed a lawsuit against Align, Thomas M. Prescott (“Mr. Prescott”), Align's President and Chief Executive Officer, and Kenneth B. Arola (“Mr. Arola”), Align's former Vice President, Finance and Chief Financial Officer, in the United States District Court for the Northern District of California on behalf of a purported class of purchasers of our common stock between April 23, 2012 and October 17, 2012 ( the "Securities Action"). The complaint alleges that Align, Mr. Prescott and Mr. Arola violated Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, and that Mr. Prescott and Mr. Arola violated Section 20(a) of the Securities Exchange Act of 1934. Specifically, the complaint alleges that during the purported class period our reported income and earnings were materially overstated because of a failure to timely write down goodwill related to the April 29, 2011 acquisition of Cadent Holdings, Inc., and that defendants made allegedly false statements concerning our forecasts. The complaint seeks monetary damages in an unspecified amount, costs and attorney's fees. The hearing on the motion for appointment of lead plaintiff is currently scheduled for May 30th, 2013. Align intends to vigorously defend itself against these allegations. Align is currently unable to predict the outcome of this complaint and therefore cannot determine the likelihood of loss nor estimate a range of possible loss.
Shareholder Derivative Lawsuit
On February 1, 2013, plaintiff Gary Udis filed a shareholder derivative lawsuit against several of Align's current and former officers and directors in the Superior Court of California, County of Santa Clara. The allegations in the complaint are similar to those presented in the Securities Action, but the complaint asserts various state law causes of action, including claims of breach of fiduciary duty, unjust enrichment, and insider trading, among others. The complaint seeks unspecified damages on behalf of Align, which is named solely as nominal defendant against whom no recovery is sought. The complaint also seeks an order directing Align to reform and improve its corporate governance and internal procedures, and seeks restitution in an unspecified amount, costs, and attorney's fees. Align intends to vigorously defend itself against these allegations. Align is currently unable to predict the outcome of this complaint and therefore cannot determine the likelihood of loss nor estimate a range of possible losses.
In addition, in the course of Align's operations, Align is involved in a variety of claims, suits, investigations, and proceedings, including actions with respect to intellectual property claims, patent infringement claims, government investigations, labor and employment claims, breach of contract claims, tax, and other matters. Regardless of the outcome, these proceedings can have an adverse impact on us because of defense costs, diversion of management resources, and other factors. Although the results of complex legal proceedings are difficult to predict and Align's view of these matters may change in the future as litigation and events related thereto unfold; Align currently does not believe that these matters, individually or in the aggregate, will materially affect Align's financial position, results of operations or cash flows.
ITEM 1A.
RISK FACTORS
We depend on the sale of the Invisalign system for the vast majority of our net revenues, and any decline in sales of Invisalign treatment for any reason, a continued weakness in general economic conditions, or a decline in average selling prices would adversely affect net revenues, gross margin and net income.
We expect that net revenues from the sale of the Invisalign system, primarily Invisalign Full and Invisalign Teen, will continue to account for the vast majority of our total net revenues for the foreseeable future. Continued and widespread market acceptance of Invisalign by orthodontists, GPs and consumers is critical to our future success. If orthodontists and GPs experience a reduction in consumer demand for orthodontic services, if consumers prove unwilling to adopt Invisalign as rapidly as we anticipate or in the volume that we anticipate, if orthodontists or GPs choose to use a competitive product rather than Invisalign or if the average selling price of our product declines, our operating results would be harmed.
Demand for our products may not increase as rapidly as we anticipate due to a variety of factors including a continued weakness in general economic conditions.
Consumer spending habits are affected by, among other things, prevailing economic conditions, levels of employment, salaries and wage rates, gas prices, consumer confidence and consumer perception of economic conditions. A general slowdown in the U.S. economy and certain international economies or an uncertain economic outlook would adversely affect
36
consumer spending habits which may, among other things, result in a decrease in the number of overall orthodontic case starts, reduced the patient traffic in dentists’ offices, reduction in consumer spending on higher value procedures or a reduction in the demand for dental services generally, each of which would have a material adverse effect on our sales and operating results. Continued weakness in the global economy results in a challenging environment for selling dental technologies and dentists may postpone investments in capital equipment, such as intra-oral scanners. In addition, Invisalign treatment, which currently accounts for the vast majority of our net revenues, represents a significant change from traditional orthodontic treatment, and customers and consumers may be reluctant to accept it or may not find it preferable to traditional treatment. We have generally received positive feedback from orthodontists, GPs and consumers regarding Invisalign treatment as both an alternative to braces and as a clinical method for treatment of malocclusion, but a number of dental professionals believe that Invisalign treatment is appropriate for only a limited percentage of their patients. Increased market acceptance of all of our products will depend in part upon the recommendations of dental professionals, as well as other factors including effectiveness, safety, ease of use, reliability, aesthetics, and price compared to competing products.
The frequency of use of the Invisalign system by orthodontists or GPs may not increase at the rate that we anticipate or at all.
One of our key objectives is to continue to increase utilization, or the adoption and frequency of use, of the Invisalign system by new and existing customers. If utilization of the Invisalign system by our existing and newly trained orthodontists or GPs does not occur or does not occur as quickly as we anticipate, our operating results could be harmed.
We may experience declines in average selling prices of our products.
In response to challenges in our business, including increased competition, we have in the past reduced the list price of our products. We also provide volume based discount programs to our doctors. In addition, we sell a number of products at different list prices. If we introduce any price reductions, or consumer rebate programs; if we expand our discount programs in the future, or participation in these programs increases; if our product mix shifts to lower priced products or products that have a higher percentage of deferred revenue; or if sales by our distributors grows at a faster pace than our direct sales, our average selling price would be adversely affected and our net revenues, gross margin and net income may be reduced. Furthermore, although the U.S. dollar is our reporting currency, a portion of our net revenues and income are generated in foreign currencies. Net revenues and income generated by subsidiaries operating outside of the United States are translated into U.S. dollars using exchange rates effective during the respective period and are affected by changes in exchange rates. As a result, negative movements in currency exchange rates against the U.S. dollar will adversely affect our average selling price and consequently the amount of net revenues and income in our consolidated financial statements.
As we continue to grow, we are subject to growth related risks, including risks related to capacity constraints at our existing facilities.
We are subject to growth related risks, including capacity constraints and pressure on our internal systems and personnel. In order to manage current operations and future growth effectively, we will need to continue to implement and improve our operational, financial and management information systems and to hire, train, motivate, manage and retain employees. We may be unable to manage such growth effectively. Any such failure could have a material adverse impact on our business, operations and prospects. In addition, in order to meet the demands from expected volumes and continued international expansion, we opened a new manufacturing facility in Juarez, Mexico at the end of 2011. We completed the transition of virtually all our scanner distribution, repair and CAD/CAM services from our New Jersey facility to this facility in Juarez, Mexico in the third quarter of 2012. In addition, in October 2012, we transitioned our intra-oral scanner research and development and manufacturing operations in Or Yehuda, Israel into a new, larger facility in the same city. Expansion can inherently include additional costs and start-up inefficiencies, as well as the inability to successfully integrate additional facilities or incremental capacity and to realize anticipated synergies, economies of scale or other value. Periods of contraction or reduced net sales, or other factors affecting particular sites, create other challenges.
Because we cannot always immediately adapt our production capacity and related cost structures to changing market conditions, our manufacturing capacity may at times exceed or fall short of our production requirements. In addition, if product demand decreases or we fail to forecast demand accurately, we could be required to write off inventory or record excess capacity charges, which would lower our gross margin. Any or all of these problems could result in the loss of customers, provide an opportunity for competing products to gain market acceptance and otherwise harm our business and financial results.
We may never achieve the anticipated benefits from our acquisitions which may have an adverse effect on our business.
37
We acquired Cadent Holdings, Inc. in April 2011. We acquired Cadent for their people, their technology and their existing revenue streams such as, OrthoCAD iRecord and OrthoCAD iCast in addition to their intra-oral scanning technology. This acquisition is expected to strengthen our ability to drive adoption of the Invisalign system by integrating Invisalign treatment more fully with mainstream tools and procedures in doctors’ practices. In addition, we believe that the combination of the two companies will help accelerate the use of intra-oral scanning in the dental industry by leveraging Align’s global sales reach, extensive professional and consumer marketing capabilities and large customer base. We completed the acquisition of our Asia-Pacific distributor on April 30, 2013. We may experience difficulties in achieving the anticipated financial or strategic benefits of these acquisitions. Potential risks include:
|
•
|
slower adoption or lack of acceptance for intra-oral scanning products in general or our chairside features;
|
|
•
|
our inability to increase utilization by integrating Invisalign treatment more fully with intra-oral scanners;
|
|
•
|
difficulty in integrating the technology, operations, internal accounting controls or work force of the acquired business with our existing business;
|
|
•
|
diversion of management resources and focus from ongoing business matters;
|
|
•
|
retention of key employees following the acquisition;
|
|
•
|
continued changes in the competitive environment, including recent announcements from competitors of new lower-priced scanners which we expect will lengthen the customer evaluation process and may result in price reductions and/or loss of sales;
|
|
•
|
difficulty dealing with tax, employment, logistics, and other related issues unique to international operations in Israel and the Asia-Pacific region;
|
|
•
|
possible impairment of relationships with employees and customers as a result of the integration;
|
|
•
|
possible inconsistencies in standards, controls, procedures and policies among the acquired businesses and Align, which may make it more difficult to implement and harmonize worldwide financial reporting, accounting, billing, information technology and other systems;
|
|
•
|
a large portion of Cadent’s operations are located in Israel, accordingly, any increase in hostilities in the Middle East involving Israel may cause interruption or suspension of business operations without warning; and
|
|
•
|
negative impact on our results of operations and financial condition from acquisition-related charges, further impairment of goodwill, impairment of intangible assets and/or asset impairment charges.
|
If we cannot successfully integrate the acquired business with our existing business, our results of operations and financial condition could be adversely affected.
If we fail to sustain or increase profitability or revenue growth in future periods, the market price for our common stock may decline.
If we are to sustain or increase profitability in future periods, we will need to continue to increase our net revenues, while controlling our expenses. Because our business is evolving, it is difficult to predict our future operating results or levels of growth, and we have in the past not been and may in the future not be able to sustain our historical growth rates. If we do not increase profitability or revenue growth or otherwise meet the expectations of securities analysts or investors, the market price of our common stock will likely decline.
Our financial results have fluctuated in the past and may fluctuate in the future which may cause volatility in our stock price.
Our operating results have fluctuated in the past and we expect our future quarterly and annual operating results to fluctuate as we focus on increasing doctor and consumer demand for our products. These fluctuations could cause our stock price to decline or significantly fluctuate. Some of the factors that could cause our operating results to fluctuate include:
|
•
|
limited visibility into and difficulty predicting the level of activity in our customers’ practices from quarter to quarter;
|
|
•
|
weakness in consumer spending as a result of the slowdown in the United States economy and global economies;
|
38
|
•
|
changes in relationships with our distributors;
|
|
•
|
changes in the timing of receipt of case product orders during a given quarter which, given our cycle time and the delay between case receipts and case shipments, could have an impact on which quarter revenue can be recognized;
|
|
•
|
fluctuations in currency exchange rates against the U.S. dollar;
|
|
•
|
changes in product mix;
|
|
•
|
our inability to predict from period to period the number of trainers or the availability of doctors required to complete intra-oral scanner installations, which may impact the timing of when revenue is recognized;
|
|
•
|
if participation in our customer rebate program increases our average selling price will be adversely affected;
|
|
•
|
seasonal fluctuations in the number of doctors in their offices and their availability to take appointments;
|
|
•
|
success of or changes to our marketing programs from quarter to quarter;
|
|
•
|
our reliance on our contract manufacturers for the production of sub-assemblies for our intra-oral scanners;
|
|
•
|
timing of industry tradeshows;
|
|
•
|
changes in the timing of when revenue is recognized, including as a result of the introduction of new products or promotions or as a result of changes to critical accounting estimates or new accounting pronouncements;
|
|
•
|
changes to our effective tax rate;
|
|
•
|
unanticipated delays in production caused by insufficient capacity or availability of raw materials;
|
|
•
|
any disruptions in the manufacturing process, including unexpected turnover in the labor force or the introduction of new production processes, power outages or natural or other disasters beyond our control;
|
|
•
|
the development and marketing of directly competitive products by existing and new competitors;
|
|
•
|
major changes in available technology or the preferences of customers may cause our current product offerings to become less competitive or obsolete;
|
|
•
|
aggressive price competition from competitors;
|
|
•
|
costs and expenditures in connection with litigation;
|
|
•
|
the timing of new product introductions by us and our competitors, as well as customer order deferrals in anticipation of enhancements or new products;
|
|
•
|
disruptions to our business due to political, economic or other social instability, including the impact of an epidemic any of which results in changes in consumer spending habits, consumers unable or unwilling to visit the orthodontist or general practitioners office, as well as any impact on workforce absenteeism;
|
|
•
|
inaccurate forecasting of net revenues, production and other operating costs; and
|
|
•
|
investments in research and development to develop new products and enhancements.
|
To respond to these and other factors, we may need to make business decisions that could adversely affect our operating results such as modifications to our pricing policy, business structure or operations. Most of our expenses, such as employee compensation and lease payment obligations, are relatively fixed in the short term. Moreover, our expense levels are based, in part, on our expectations regarding future revenue levels. As a result, if our net revenues for a particular period fall below our expectations, whether caused by changes in consumer spending, consumer preferences, weakness in the U.S. or global economies, changes in customer behavior related to advertising and prescribing our product, or other factors, we may be unable to adjust spending quickly enough to offset any shortfall in net revenues. Due to these and other factors, we believe that quarter-to-quarter comparisons of our operating results may not be meaningful. You should not rely on our results for any one quarter as an indication of our future performance.
39
Our future success may depend on our ability to develop, successfully introduce and achieve market acceptance of new products.
Our future success may depend on our ability to develop, manufacture, market, and obtain regulatory approval or clearance of new products. There can be no assurance that we will be able to successfully develop, sell and achieve market acceptance of these and other new products and applications and enhanced versions of our existing product or software. The extent of, and rate at which, market acceptance and penetration are achieved by future products is a function of many variables, which include, among other things, our ability to:
|
•
|
correctly identify customer needs and preferences and predict future needs and preferences;
|
|
•
|
include functionality and features that address customer requirements;
|
|
•
|
ensure compatibility of our computer operating systems and hardware configurations with those of our customers;
|
|
•
|
allocate our research and development funding to products with higher growth prospects;
|
|
•
|
anticipate and respond to our competitors’ development of new products and technological innovations;
|
|
•
|
differentiate our offerings from our competitors’ offerings;
|
|
•
|
innovate and develop new technologies and applications;
|
|
•
|
the availability of third-party reimbursement of procedures using our products;
|
|
•
|
obtain adequate intellectual property rights; and
|
|
•
|
encourage customers to adopt new technologies.
|
If we fail to accurately predict customer needs and preferences or fail to produce viable technologies, we may invest heavily in research and development of products that do not lead to significant revenue. Even if we successfully innovate and develop new products and produce enhancements, we may incur substantial costs in doing so, and our profitability may suffer. In addition, even if our new products are successfully introduced, it is unlikely that they will rapidly gain market share and acceptance primarily due to the relatively long period of time it takes to successfully treat a patient with the Invisalign system. Since it takes approximately 12 to 24 months to treat a patient, our customers may be unwilling to rapidly adopt our new products until they successfully complete at least one case or until more historical clinical results are available.
Our ability to market and sell new products may also be subject to government regulation, including approval or clearance by the United States Food and Drug Administration (“FDA”), and foreign government agencies. Any failure in our ability to successfully develop and introduce or achieve market acceptance of our new products or enhanced versions of existing products could have a material adverse effect on our operating results and could cause our net revenues to decline.
A disruption in the operations of our primary freight carrier or higher shipping costs could cause a decline in our net revenues or a reduction in our earnings.
We are dependent on commercial freight carriers, primarily UPS, to deliver our products to our customers. If the operations of these carriers are disrupted for any reason, we may be unable to deliver our products to our customers on a timely basis. If we cannot deliver our products in an efficient and timely manner, our customers may reduce their orders from us and our net revenues and operating profits could materially decline. In a rising fuel cost environment, our freight costs will increase. If freight costs materially increase and we are unable to pass that increase along to our customers for any reason or otherwise offset such increases in our cost of net revenues, our gross margin and financial results could be adversely affected.
We are dependent on our international operations, which exposes us to foreign operational, political and other risks that may harm our business.
Our key production steps are performed in operations located outside of the U.S. At our facility in Costa Rica, technicians use a sophisticated, internally developed computer-modeling program to prepare digital treatment plans, which are then transmitted electronically to Juarez, Mexico. These digital files form the basis of the ClinCheck treatment plan and are used to manufacture aligner molds. Our order acquisition, aligner fabrication and shipping operations are conducted in Juarez, Mexico. In addition to the research and development efforts conducted in our San Jose, California facility, we also carry out research and development at locations in San Jose, Costa Rica and Moscow, Russia. In addition, our customer-care, accounts receivable, credit and collections and customer event registration organizations are located at our facility in Costa Rica. We also
40
have operations in Israel where the design and wand assembly, intra-oral scanner manufacturing and digital modeling of our intra-oral scanners occurs. Our reliance on international operations exposes us to risks and uncertainties that may affect our business or results of operation, including:
|
•
|
difficulties in hiring and retaining employees generally, as well as difficulties in hiring and retaining employees with the necessary skills to perform the more technical aspects of our operations;
|
|
•
|
difficulties in managing international operations;
|
|
•
|
fluctuations in currency exchange rates;
|
|
•
|
import and export license requirements and restrictions;
|
|
•
|
controlling production volume and quality of the manufacturing process;
|
|
•
|
political, social and economic instability, including as a result of increased levels of violence in Juarez, Mexico or the Middle East;
|
|
•
|
acts of terrorism and acts of war;
|
|
•
|
interruptions and limitations in telecommunication services;
|
|
•
|
product or material transportation delays or disruption, including as a result of health epidemics restricting travel to and from our international locations or as a result of natural disasters, such as earthquakes or volcanic eruptions;
|
|
•
|
burdens of complying with a wide variety of local country and regional laws;
|
|
•
|
trade restrictions and changes in tariffs; and
|
|
•
|
potential adverse tax consequences.
|
If any of these risks materialize in the future, we could experience production delays and lost or delayed revenue.
We earn an increasingly larger portion of our total revenues from international sales and face risks attendant to those operations.
We earn an increasingly larger portion of our total revenues from international sales generated through our foreign direct and indirect operations. As a result of these sales operations, we face a variety of risks, including
|
•
|
local political and economic instability;
|
|
•
|
the engagement of activities by our employees, contractors, partners and agents, especially in countries with developing economies, that are prohibited by international and local trade and labor laws and other laws prohibiting corrupt payments to government officials, including the Foreign Corrupt Practices Act, the UK Bribery Act of 2010 and export control laws, in spite of our policies and procedures designed to ensure compliance with these laws;
|
|
•
|
restrictions on the transfer of funds, including with respect to restrictions on our ability to repatriate foreign cash to the United States at favorable tax rates;
|
|
•
|
fluctuations in currency exchange rates; and
|
|
•
|
increased expense of developing, testing and making localized versions of our products;
|
Any of these factors, either individually or in combination, could materially impact our international operations and adversely affect our business as a whole.
A key step in our manufacturing process relies on sophisticated computer technology that requires new technicians to undergo a relatively long training process. If we are unable to accurately predict our volume growth, and fail to hire a sufficient number of technicians in advance of such demand, the delivery time of our products could be delayed which could adversely affect our results of operations.
41
Training production technicians takes approximately 90 to 120 days. As a result, if we are unable to accurately predict our volume growth, we may not have a sufficient number of trained technicians to deliver our products within the timeframe our customers expect. Such a delay could cause us to lose existing customers or fail to attract new customers. This could cause a decline in our net revenues and net income and could adversely affect our results of operations.
Our headquarters, digital dental modeling processes, and other manufacturing processes are principally located in regions that are subject to earthquakes and other natural disasters.
Our digital dental modeling is processed in our facility located in San Jose, Costa Rica. The operations team in Costa Rica creates ClinCheck treatment plans using sophisticated computer software. In addition, our customer facing operations are located in Costa Rica. Our aligner molds and finished aligners are fabricated in Juarez, Mexico. Both Costa Rica and Mexico are in earthquake zones and may be subject to other natural disasters. If there is a major earthquake or any other natural disaster in a region where one of these facilities is located, our ability to create ClinCheck treatment plans, respond to customer inquiries or manufacture and ship our aligners could be compromised which could result in our customers experiencing a significant delay in receiving their completed aligners and a decrease in service levels for a period of time. In addition, our headquarters facility is located in the San Francisco Bay Area. An earthquake or other natural disaster in this region could result in a disruption in our operations. Any such business interruption could materially and adversely affect our business, financial condition and results of operations.
Competition in the markets for our products is intense and we expect aggressive competition from existing competitors and other companies that may introduce new technologies in the future.
Currently, our products compete directly against products manufactured and distributed by various companies, both within and outside the United States. Many of these manufacturers, including Danaher Corporation, 3M, Sirona Dental Systems, Inc. and Dentsply International, have substantially greater financial resources and manufacturing and marketing experience than we do and may, in the future, attempt to develop an orthodontic system similar to ours or combine technologies that make our product economically unattractive. The expiration of key certain patents commencing in 2017 owned by us may result in additional competition. Large consumer product companies may also enter the orthodontic supply market. Furthermore, we may face competition in the future from new companies that may introduce new technologies. We may be unable to compete with these competitors and one or more of these competitors may render our technology obsolete or economically unattractive. If we are unable to compete effectively with existing products or respond effectively to any products developed by new or existing competitors, our business could be harmed. Increased competition has resulted in the past and may in the future result in volume discounting and price reductions, reduced gross margins, reduced profitability and loss of market share, and reduce dental professionals’ efforts and commitment to expand their use of our products, any of which could have a material adverse effect on our net revenues, volume growth, net income (losses) and stock price. We cannot assure you that we will be able to compete successfully against our current or future competitors or that competitive pressures will not have a material adverse effect on our business, results of operations and financial condition.
Our information technology systems are critical to our business. System integration and implementation issues and system security risks could disrupt our operations, which could have a material adverse impact on our business and operating results.
We rely on the efficient and uninterrupted operation of complex information technology systems. All information technology systems are vulnerable to damage or interruption from a variety of sources. As our business has grown in size and complexity, the growth has placed, and will continue to place, significant demands on our information technology systems. To effectively manage this growth, our information systems and applications require an ongoing commitment of significant resources to maintain, protect and enhance existing systems and develop new systems to keep pace with continuing changes in information processing technology, evolving industry and regulatory standards and changing customer preferences. If the information we rely upon to run our businesses were to be found to be inaccurate or unreliable, if we fail to properly maintain our information systems and data integrity, or if we fail to develop new capabilities to meet our business needs in a timely manner, we could have operational disruptions, have customer disputes, lose our ability to produce timely and accurate reports, have regulatory or other legal problems, have increases in operating and administrative expenses, lose existing customers, have difficulty in attracting new customers or in implementing our growth strategies, or suffer other adverse consequences. In addition, experienced computer programmers and hackers may be able to penetrate our network security and misappropriate our confidential information or that of third parties, create system disruptions or cause shutdowns. Furthermore, sophisticated hardware and operating system software and applications that we either internally develop or procure from third parties may contain defects in design and manufacture, including “bugs” and other problems that can unexpectedly interfere with the operation of the system. The costs to eliminate or alleviate security problems, viruses and bugs could be significant, and the
42
efforts to address these problems could result in interruptions that may have a material adverse impact on our operations, net revenues and operating results.
We are currently focused on adding more functionality into our business enterprise systems to more efficiently integrate these systems with our other system applications, such as customer facing and manufacturing tools, and intend to continue this effort for the foreseeable future. System upgrades and enhancements require significant expenditures and allocation of valuable employee resources. Delays in integration or disruptions to our business from implementation of these new or upgraded systems could have a material adverse impact on our financial condition and operating results.
Additionally, we continuously upgrade our customer facing software applications, specifically the ClinCheck and MyAligntech software. Software applications frequently contain errors or defects, especially when they are first introduced or when new versions are released. The discovery of a defect or error or the incompatibility with the computer operating system and hardware configurations of customers in a new upgraded version or the failure of our primary information systems may result in the following consequences, among others: loss of revenue or delay in market acceptance, damage to our reputation or increased service costs, any of which could have a material adverse effect on our business, financial condition or results of operations.
Furthermore, our business requires the secure transmission of confidential information over public networks. Because of the confidential health information we store and transmit, security breaches could expose us to a risk of regulatory action, litigation, possible liability and loss. Our security measures may be inadequate to prevent security breaches, and our business operations and profitability would be adversely affected by, among other things, loss of customers and potential criminal and civil sanctions if they are not prevented.
There can be no assurance that our process of improving existing systems, developing new systems to support our expanding operations, integrating new systems, protecting confidential patient information, and improving service levels will not be delayed or that additional systems issues will not arise in the future. Failure to adequately protect and maintain the integrity of our information systems and data may result in a material adverse effect on our financial position, results of operations and cash flows.
If the security of our customer and patient information is compromised, patient care could suffer, and we could be liable for related damages, and our reputation could be impaired.
We retain confidential customer and patient information in our processing centers. Therefore, it is critical that our facilities and infrastructure remain secure and that our facilities and infrastructure are perceived by the marketplace and our customers to be secure. Despite the implementation of security measures, our infrastructure may be vulnerable to physical break-ins, computer viruses, programming errors, attacks by third parties or similar disruptive problems. If we fail to meet our clients’ expectations regarding the security of healthcare information, we could be liable for damages and our reputation could be impaired. In addition, patient care could suffer, and we could be liable if our systems fail to deliver correct information in a timely manner. Our insurance may not protect us from this risk.
Our success depends in part on our proprietary technology, and if we are unable to successfully enforce our intellectual property rights, our competitive position may be harmed. Litigating claims of this type is costly and could distract our management and cause a decline in our results of operations and stock price.
Our success will depend in part on our ability to maintain existing intellectual property and to obtain and maintain further intellectual property protection for our products, both in the U.S. and in other countries. Our inability to do so could harm our competitive position. As of
March 31, 2013
, we had issued 289 U.S. patents, 138 pending U.S. patent applications, and 231 foreign issued patents, and 130 pending foreign patent applications.
We intend to rely on our portfolio of issued and pending patent applications in the U.S. and in other countries to protect a large part of our intellectual property and our competitive position. However, our currently pending or future patent filings may not result in the issuance of patents. Additionally, any patents issued to us may be challenged, invalidated, held unenforceable, circumvented, or may not be sufficiently broad to prevent third parties from producing competing products similar in design to our products. In addition, any protection afforded by foreign patents may be more limited than that provided under U.S. patents and intellectual property laws. We also rely on protection of our copyrights, trade secrets, know-how and proprietary information. We generally enter into confidentiality agreements with our employees, consultants and our collaborative partners upon commencement of a relationship with us. However, these agreements may not provide meaningful protection against the unauthorized use or disclosure of our trade secrets or other confidential information, and adequate remedies may not exist if unauthorized use or disclosure were to occur. Our inability to maintain the proprietary nature of our technology through
43
patents, copyrights or trade secrets would impair our competitive advantages and could have a material adverse effect on our operating results, financial condition and future growth prospects. In particular, a failure to protect our proprietary rights might allow competitors to copy our technology, which could adversely affect our pricing and market share. In addition, in an effort to protect our intellectual property we have in the past been and may in the future be involved in litigation. The potential effects on our business operations resulting from litigation that we may participate in the future, whether or not ultimately determined in our favor or settled by us, are costly and divert the efforts and attention of our management and technical personnel from normal business operations.
Litigation is subject to inherent uncertainties and unfavorable rulings could occur. An unfavorable ruling could include monetary damages or, in cases where injunctive relief is sought, an injunction prohibiting us from selling our products. Any of these results from our litigation could adversely affect our results of operations and stock price.
While we believe we currently have adequate internal control over financial reporting, we are required to assess our internal control over financial reporting on an annual basis and any future adverse results from such assessment could result in a loss of investor confidence in our financial reports and have an adverse effect on our stock price.
Pursuant to the Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated by the SEC, we are required to furnish in our Form 10-K a report by our management regarding the effectiveness of our internal control over financial reporting. The report includes, among other things, an assessment of the effectiveness of our internal control over financial reporting as of the end of our fiscal year, including a statement as to whether or not our internal control over financial reporting is effective. This assessment must include disclosure of any material weaknesses in our internal control over financial reporting identified by management. While we believe our internal control over financial reporting is currently effective, the effectiveness of our internal controls to future periods is subject to the risk that our controls may become inadequate because of changes in conditions, and, as a result, the degree of compliance of our internal control over financial reporting with the policies or procedures may deteriorate. Establishing, testing and maintaining an effective system of internal control over financial reporting requires significant resources and time commitments on the part of our management and our finance staff, may require additional staffing and infrastructure investments, and would increase our costs of doing business. If we are unable to assert that our internal control over financial reporting is effective in any future period (or if our auditors are unable to express an opinion on the effectiveness of our internal controls or conclude that our internal controls are ineffective), we could lose investor confidence in the accuracy and completeness of our financial reports, which could have an adverse effect on our stock price.
If our goodwill or long-lived assets become impaired, we may be required to record a significant charge to earnings.
Under Generally Accepted Accounting Principles in the United States (“U.S. GAAP”), we review our goodwill and asset group for impairment when events or changes in circumstances indicate the carrying value may not be recoverable. Additionally, goodwill is required to be tested for impairment at least annually. The valuations used to determine the fair values used to test goodwill and the undiscounted cash flows used to evaluate the recoverability of the asset group are dependent upon various assumptions and reflect management’s best estimates. Changes in certain assumptions including revenue growth rates, discount rates, earnings multiples and future cash flows may cause a change in circumstances indicating that the carrying value of goodwill or the asset group may be impaired. We may be required to record a significant charge to earnings in the financial statements during the period in which any impairment of goodwill or asset group are determined.
Recent changes in the competitive environment, including announcements in March 2013 of new lower-priced scanners targeted at Orthodontists and GPs in North America caused us to lower our expectations for growth and profitability for scanner and CAD/CAM services business. As a result, we conducted an impairment analysis of long-lived assets and goodwill related to the SCCS reporting unit. Based on these analyses, we recorded a $26.3 million impairment of our long-lived assets and $40.7 million impairment of goodwill. The $40.7 million represents the remaining goodwill balance in the SCCS reporting unit.
If we lose our key personnel or are unable to attract and retain key personnel, we may be unable to pursue business opportunities or develop our products.
We are highly dependent on the key employees in our clinical engineering, technology development, sales, training and marketing personnel and management teams. The loss of the services provided by those individuals may significantly delay or prevent the achievement of our product development and other business objectives and could harm our business. Our future success will also depend on our ability to identify, recruit, train and retain additional qualified personnel, including orthodontists. Few orthodontists are accustomed to working in a manufacturing environment since they are generally trained to
44
work in private practices, universities and other research institutions. Thus, we may be unable to attract and retain personnel with the advanced qualifications necessary for the further development of our business. Furthermore, we may not be successful in retaining our key personnel or their services. If we are unable to attract and retain key personnel, our business could be materially harmed. We had two executive departures in fiscal 2012 and we recently announced the departure of our Chief Financial Officer effective March 4, 2013. While we have since hired replacements for the 2012 departures and are currently conducting a search for a new CFO, there is always risk of uncertainty and instability relating to our ability to find highly qualified successors for certain executive positions and to transition the duties and responsibilities of any departing key executive in an orderly manner. In addition, our ability to recognize revenue on the direct sales of our intra-oral scanners depends in part upon our ability to schedule and staff trainings. The loss of the services provided by these individuals or our ability to timely hire such personnel in sufficient numbers based on our volume growth, may harm our business. If we are unable to retain our trainers or replace such individuals with persons having equivalent technical expertise and qualifications, or if we are unable to successfully instill such technical expertise in newly hired personnel or accurately predict the number of such personnel needed, our net revenues could be materially harmed.
If we infringe the patents or proprietary rights of other parties or are subject to a patent infringement claim, our ability to grow our business may be severely limited.
Extensive litigation over patents and other intellectual property rights is common in the medical device industry. We have been sued for infringement of third party’s patents in the past and we may be the subject of patent or other litigation in the future. From time to time, we have received and may in the future receive letters from third parties drawing our attention to their patent rights. While we do not believe that we infringe upon any valid and enforceable rights that have been brought to our attention, there may be other more pertinent rights of which we are presently unaware. The defense and prosecution of intellectual property suits, interference proceedings and related legal and administrative proceedings could result in substantial expense to us and significant diversion of effort by our technical and management personnel. An adverse determination of any litigation or interference proceeding to which we may become a party could subject us to significant liabilities. An adverse determination of this nature could also put our patents at risk of being invalidated or interpreted narrowly or require us to seek licenses from third parties. Licenses may not be available on commercially reasonable terms or at all, in which event, our business would be materially adversely affected.
We maintain single supply relationships for certain of our key machines and materials technologies, and our business and operating results could be harmed if supply is restricted or ends or the price of raw materials used in our manufacturing process increases.
We are highly dependent on manufacturers of specialized scanning equipment, rapid prototyping machines, resin and other advanced materials, as well as the optics, electronic and other mechanical components of our intra-oral scanners. We maintain single supply relationships for many of these machines and materials technologies. In particular, our CT scanning and stereolithography equipment used in our aligner manufacturing and many of the critical components for the optics of our scanners are provided by single suppliers. We are also committed to purchasing all of our resin and polymer, the primary raw materials used in our manufacturing process for clear aligners, from a single source. If these or other suppliers encounter financial, operating or other difficulties or if our relationship with them changes, we might not be able to quickly establish or qualify replacement sources of supply and could face production interruptions, delays and inefficiencies. In addition, technology changes by our vendors could disrupt access to required manufacturing capacity or require expensive, time consuming development efforts to adapt and integrate new equipment or processes. Our growth may exceed the capacity of one or more of these manufacturers to produce the needed equipment and materials in sufficient quantities to support our growth. Conversely, in order to secure supplies for production of products, we sometimes enter into non-cancelable purchase commitments with vendors, which could impact our ability to adjust our inventory to reflect declining market demands. If demand for our products is less than we expect, we may experience additional excess and obsolete inventories and be forced to incur additional charges and our profitability may suffer. In the event of technology changes, delivery delays, or shortages of or increases in price for these items, our business and growth prospects may be harmed.
We depend on a single contract manufacturer and supplier of parts used in our iTero scanner and any disruption in this relationship may cause us to fail to meet the demands of our customers and damage our customer relationships.
We rely on a third party manufacturer in Israel to assemble our iTero scanner. As a result, if this third party manufacturer fails to deliver its components or if we lose its services, we may be unable to deliver our products in a timely manner and our business may be harmed. Any difficulties encountered by the third party manufacturer with respect to hiring personnel, and maintaining acceptable manufacturing standards, controls, procedures and policies could disrupt our ability to deliver our products in a timely manner. Finding a substitute manufacturer may be expensive, time-consuming or impossible and could result in a significant interruption in the supply of our intra-oral scanning products. Any failure by our contract manufacturer
45
that results in delays in our fulfillment of customer orders may cause us to lose revenues and suffer damage to our customer relationships.
We primarily rely on our direct sales force to sell our products, and any failure to maintain our direct sales force could harm our business.
Our ability to sell our products and generate revenues primarily depends upon our direct sales force within our North American and international markets. As of
March 31, 2013
, our North American sales organization consisted of approximately 245 people. Internationally, we had approximately 85 people engaged in sales and sales support as of
March 31, 2013
. We do not have any long-term employment contracts with the members of our direct sales force. The loss of the services provided by these key personnel may harm our business. If we are unable to retain our direct sales force personnel or replace them with individuals of equivalent technical expertise and qualifications, or if we are unable to successfully instill such technical expertise or if we fail to establish strong relationships with our customers within a relatively short period of time, our net revenues and our ability to maintain market share could be materially harmed. In addition, due to our large and fragmented customer base, we may not be able to provide all of our customers with product support immediately upon the launch of a new product. As a result, adoption of new products by our customers may be slower than anticipated and our ability to grow market share and increase our net revenues may be harmed.
If our distributor relationships are not successful, our ability to market and sell our products would be harmed and our financial performance will be adversely affected.
We depend on relationships with distributors for the marketing and sales of our products in various geographic regions, and we have a limited ability to influence their efforts. Relying on distributors for our sales and marketing could harm our business for various reasons, including:
|
•
|
agreements with distributors may terminate prematurely due to disagreements or may result in litigation between the partners;
|
|
•
|
we may not be able to renew existing distributor agreements on acceptable terms;
|
|
•
|
our distributors may not devote sufficient resources to the sale of products;
|
|
•
|
our distributors may be unsuccessful in marketing our products;
|
|
•
|
our existing relationships with distributors may preclude us from entering into additional future arrangements with other distributors; and
|
|
•
|
we may not be able to negotiate future distributor agreements on acceptable terms.
|
Complying with regulations enforced by the FDA and other regulatory authorities is an expensive and time-consuming process, and any failure to comply could result in substantial penalties.
Our products are medical devices and are subject to extensive regulation in the U.S. and internationally. FDA regulations are wide ranging and govern, among other things:
|
•
|
product design, development, manufacturing and testing;
|
|
•
|
product labeling;
|
|
•
|
product storage;
|
|
•
|
pre-market clearance or approval;
|
|
•
|
advertising and promotion; and
|
|
•
|
product sales and distribution.
|
Our failure to comply with applicable regulatory requirements could result in enforcement action by the FDA or state agencies, which may include any of the following sanctions:
|
•
|
warning letters, fines, injunctions, consent decrees and civil penalties;
|
|
•
|
repair, replacement, refunds, recall or seizure of our products;
|
46
|
•
|
operating restrictions or partial suspension or total shutdown of production;
|
|
•
|
refusing our requests for 510(k) clearance or pre-market approval of new products, new intended uses, or modifications to existing products;
|
|
•
|
withdrawing clearance or pre-market approvals that have already been granted; and
|
|
•
|
criminal prosecution.
|
If any of these events were to occur, they could harm our business. We must comply with facility registration and product listing requirements of the FDA and adhere to applicable Quality System regulations. The FDA enforces its Quality System regulations through periodic unannounced inspections. Our failure to take satisfactory corrective action in response to an adverse inspection or the failure to comply with applicable manufacturing regulations could result in enforcement action, and we may be required to find alternative manufacturers, which could be a long and costly process. Any FDA enforcement action could have a material adverse effect on us.
Before we can sell a new medical device in the U.S., or market a new use of or claim for an existing product we must obtain FDA clearance or approval, unless an exemption applies. Obtaining regulatory clearances or approvals can be a lengthy and time-consuming process. Even though the devices we market have obtained the necessary clearances from the FDA, we may be unable to maintain such clearances in the future. Furthermore, we may be unable to obtain the necessary clearances for new devices that we intend to market in the future. Our inability to maintain or obtain regulatory clearances or approvals could materially harm our business.
If compliance with healthcare regulations becomes costly and difficult for our customers or for us, we may not be able to grow our business.
Participants in the healthcare industry are subject to extensive and frequently changing regulations under numerous laws administered by governmental entities at the federal, state and local levels, some of which are, and others of which may be, applicable to our business. In response to perceived increases in health care costs in recent years, Congress recently passed health care reform legislation that President Obama signed into law in March 2010. The enacted legislation contains many provisions designed to generate the revenues necessary to fund the coverage expansions. The most relevant of these provisions are those that impose fees or taxes on certain health-related industries, including medical device manufacturers. Beginning in 2013, each medical device manufacturer will have to pay an excise tax in an amount equal to 2.3 percent of the price for which such manufacturer sells its medical devices in the U.S. This tax applies to all medical devices, including our products, which could have a material, negative impact on our results of operations and our cash flows.
Furthermore, our healthcare provider customers are also subject to a wide variety of laws and regulations that could affect the nature and scope of their relationships with us. The healthcare market itself is highly regulated and subject to changing political, economic and regulatory influences. Regulations implemented pursuant to the Health Insurance Portability and Accountability Act (HIPAA), including regulations affecting the security and privacy of patient healthcare information held by healthcare providers and their business associates may require us to make significant and unplanned enhancements of software applications or services, result in delays or cancellations of orders, or result in the revocation of endorsement of our products and services by healthcare participants. The effect of HIPAA and newly enforced regulations on our business is difficult to predict, and there can be no assurance that we will adequately address the business risks created by HIPAA and its implementation or that we will be able to take advantage of any resulting business opportunities.
Extensive and changing government regulation of the healthcare industry may be expensive to comply with and exposes us to the risk of substantial government penalties.
In addition to medical device laws and regulations, numerous state and federal healthcare-related laws regulate our business, covering areas such as:
|
•
|
storage, transmission and disclosure of medical information and healthcare records;
|
|
•
|
prohibitions against the offer, payment or receipt of remuneration to induce referrals to entities providing healthcare services or goods or to induce the order, purchase or recommendation of our products; and
|
|
•
|
the marketing and advertising of our products.
|
Complying with these laws and regulations could be expensive and time-consuming, and could increase our operating costs or reduce or eliminate certain of our sales and marketing activities or our revenues.
47
We face risks related to our international sales, including the need to obtain necessary foreign regulatory clearance or approvals.
Outside of North America, we currently sell our products in Europe, Asia-Pacific, Latin America and the Middle East and may expand into other countries from time to time. For sales of our products outside the U.S., we are subject to foreign regulatory requirements that vary widely from country to country. The time required to obtain clearances or approvals required by other countries may be longer than that required for FDA clearance or approval, and requirements for such approvals may differ from FDA requirements. We may be unable to obtain regulatory approvals in one or more of the other countries in which we do business or in which we may do business in the future. We may also incur significant costs in attempting to obtain and maintain foreign regulatory approvals. If we experience delays in receipt of approvals to market our products outside of the U.S., or if we fail to receive these approvals, we may be unable to market our products or enhancements in international markets in a timely manner, if at all.
Our business exposes us to potential product liability claims, and we may incur substantial expenses if we are subject to product liability claims or litigation.
Medical devices involve an inherent risk of product liability claims and associated adverse publicity. We may be held liable if any product we develop or any product that uses or incorporates any of our technologies causes injury or is otherwise found unsuitable. Although we intend to continue to maintain product liability insurance, adequate insurance may not be available on acceptable terms, if at all, and may not provide adequate coverage against potential liabilities. A product liability claim, regardless of its merit or eventual outcome, could result in significant legal defense costs. These costs would have the effect of increasing our expenses and diverting management’s attention away from the operation of our business, and could harm our business.
Historically, the market price for our common stock has been volatile.
The market price of our common stock could be subject to wide price fluctuations in response to various factors, many of which are beyond our control. The factors include:
|
•
|
quarterly variations in our results of operations and liquidity;
|
|
•
|
changes in recommendations by the investment community or in their estimates of our net revenues or operating results;
|
|
•
|
speculation in the press or investment community concerning our business and results of operations;
|
|
•
|
strategic actions by our competitors, such as product announcements or acquisitions;
|
|
•
|
announcements of technological innovations or new products by us, our customers or competitors; and
|
|
•
|
general economic market conditions.
|
In addition, the stock market in general, and the market for technology and medical device companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated to or disproportionate to the operating performance of those companies. These broad market and industry factors may seriously harm the market price of our common stock, regardless of our operating performance. Historically, class action litigation is often brought against an issuing company following periods of volatility in the market price of a company’s securities.
Future sales of significant amounts of our common stock may depress our stock price.
A large percentage of our outstanding common stock is currently owned by a small number of significant stockholders. These stockholders have sold in the past, and may sell in the future, large amounts of common stock over relatively short periods of time. Sales of substantial amounts of our common stock in the public market by our existing stockholders may adversely affect the market price of our common stock. Such sales could create public perception of difficulties or problems with our business and may depress our stock price.
Changes in, or interpretations of, accounting rules and regulations, could result in unfavorable accounting charges.
We prepare our consolidated financial statements in conformity with U.S. GAAP. These principles are subject to interpretation by the Securities and Exchange Commission ("SEC") and various bodies formed to interpret and create appropriate accounting policies. A change in these policies can have a significant effect on our reported results and may even
48
retroactively affect previously reported transactions. Our accounting policies that recently have been or may be affected by changes in the accounting rules are as follows:
|
•
|
revenue recognition; and
|
|
•
|
leases.
|
If we fail to manage our exposure to global financial and securities market risk successfully, our operating results and financial statements could be materially impacted.
The primary objective of most of our investment activities is to preserve principal. To achieve this objective, a majority of our marketable investments are investment grade, liquid, short-term fixed-income securities and money market instruments denominated in U.S. dollars. If the carrying value of our investments exceeds the fair value, and the decline in fair value is deemed to be other-than-temporary, we will be required to write down the value of our investments, which could materially harm our results of operations and financial condition. Moreover, the performance of certain securities in our investment portfolio correlates with the credit condition of the U.S. financial sector. In an current unstable credit environment, we might incur significant realized, unrealized or impairment losses associated with these investments.
We have adopted a shareholders rights’ plan to limit the possibility that we are acquired, which may mean that a transaction that shareholders are in favor of or are benefited by may be prevented.
Our board of directors has the authority to issue up to 5,000,000 shares of preferred stock and to determine the rights, preferences, privileges and restrictions of such shares without any further vote or action by our shareholders. To date, our board of directors has designated 200,000 shares as Series A participating preferred stock in connection with our shareholder rights’ plan. The issuance of preferred stock under certain circumstances could have the effect of delaying or preventing an acquisition of Align or otherwise adversely affecting the rights of the holders of our stock. The shareholder rights’ plan may have the effect of rendering more difficult or discouraging an acquisition of our company which is deemed undesirable by our board of directors. The shareholder rights’ plan may cause substantial dilution to a person or group attempting to acquire us on terms or in a manner not approved by our board of directors, except pursuant to an offer conditioned on the negation, purchase or redemption of the rights issued under the shareholder rights’ plan.
Our effective tax rate may vary significantly from period to period.
Various internal and external factors may have favorable or unfavorable effects on our future effective tax rate. These factors include, but are not limited to, changes in tax laws, regulations and/or rates, non-deductible goodwill impairments, changing interpretations of existing tax laws or regulations, changes in the relative proportions of revenues and income before taxes in the various jurisdictions in which we operate that have differing statutory tax rates, the future levels of tax benefits of stock option deductions relating to incentive stock options and employee stock purchase plans, settlement of income tax audits, and changes in overall levels of pretax earnings. During the first quarter of 2013, we incurred a $40.7 million impairment of goodwill which was not deductible for tax purposes.
In June 2009, the Costa Rica Ministry of Foreign Trade, an agency of the Government of Costa Rica, granted a twelve year extension of the tax incentives which were previously granted in 2002. Under these incentives, all of the income we earn in Costa Rica during these twelve year incentive periods is subject to reduced rates of Costa Rica income tax. The incentive tax rates will expire in various years beginning in 2017. The Costa Rica corporate income tax rate that would apply, absent the incentives, is 30% for 2013. As a result of these incentives, income taxes were reduced by $6.0 million through the first quarter of 2013 In order to receive the benefit of the incentives, we must hire specified numbers of employees and maintain minimum levels of fixed asset investment in Costa Rica. If we do not fulfill these conditions for any reason, our incentive could lapse and our income in Costa Rica would be subject to taxation at higher rates, which could have a negative impact on our operating results. Our subsidiaries in Israel and Germany are under audit by the local tax authorities for calendar years 2006 through 2011 and 2007 through 2011, respectively.
ITEM 2.
UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
Following is a summary of stock repurchases for the three months ended
March 31, 2013
(1):
49
|
Period
|
Total Number of Shares Repurchased
|
Average Price Paid per Share
|
Total Number of Shares Repurchased as Part of Publicly Announced Program
|
Approximate Dollar Value of Shares that May Yet Be Repurchased Under the Program
|
||||||||||
|
January 1, 2013 through March 31, 2013
|
75,000
|
|
$
|
32.47
|
|
75,000
|
|
$
|
92,617,098
|
|
||||
On October 27, 2011, we announced that our Board of Directors approved a stock repurchase program pursuant to which we may repurchase up to $150.0 million of common stock subject to market conditions, share price and other considerations. Purchases under the stock repurchase program may be made from time to time in the open market. During the first quarter of 2013, we repurchased approximately
0.1 million
shares of common stock at an average price of
$32.47
per share for an aggregate purchase price of approximately
$2.4 million
including commissions. The common stock repurchases reduced additional paid-in capital by approximately
$0.7 million
and increased accumulated deficit by
$1.7 million
. All repurchased shares were retired.
|
(1)
|
All shares were repurchased pursuant to the publicly announced repurchase program described above.
|
ITEM 3.
DEFAULTS UPON SENIOR SECURITIES
Not applicable.
ITEM 4.
MINE SAFETY DISCLOSURES
Not applicable.
None
(a) Exhibits:
|
Exhibit
Number
|
Description
|
Filing
|
Date
|
Exhibit
Number
|
Filed here with
|
|||||
|
10.1
|
Transition Agreement between Kenneth B. Arola and Align Technology, Inc.
|
*
|
||||||||
|
10.2
|
Credit Agreement, dated as of March 22, 2013, by and between Align Technology, Inc., as borrower, and Wells Fargo Bank, National Association, as lender.
|
8-K
|
3/27/2013
|
10.1
|
||||||
|
31.1
|
Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
*
|
||||||||
|
31.2
|
Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
*
|
||||||||
|
32.1
|
Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
*
|
||||||||
|
101.INS
|
XBRL Instance Document
|
*
|
||||||||
|
101.SCH
|
XBRL Taxonomy Extension Schema Document
|
*
|
||||||||
|
101.CAL
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
*
|
||||||||
|
101.DEF
|
XBRL Taxonomy Extension Definition Linkbase Document
|
*
|
||||||||
|
101.LAB
|
XBRL Taxonomy Extension Label Linkbase Document
|
*
|
||||||||
|
101.PRE
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
*
|
||||||||
50
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
ALIGN TECHNOLOGY, INC.
|
|
|
Date: May 3, 2013
|
By:
|
/
S
/ T
HOMAS
M. P
RESCOTT
|
|
Thomas M. Prescott
President and Chief Executive Officer
|
||
|
By:
|
/
S
/ ROGER E. GEORGE
|
|
|
Roger E. George
Vice President, Corporate and Legal Affairs, General Counsel and Interim Chief Financial Officer
|
||
51
EXHIBIT INDEX
|
Exhibit
Number
|
Description
|
Filing
|
Date
|
Exhibit
Number
|
Filed here with
|
|||||
|
10.1
|
Transition Agreement between Kenneth B. Arola and Align Technology, Inc.
|
*
|
||||||||
|
10.2
|
Credit Agreement, dated as of March 22, 2013, by and between Align Technology, Inc., as borrower, and Wells Fargo Bank, National Association, as lender.
|
8-K
|
3/27/2013
|
10.1
|
||||||
|
31.1
|
Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
*
|
||||||||
|
31.2
|
Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
*
|
||||||||
|
32.1
|
Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
*
|
||||||||
|
101.INS
|
XBRL Instance Document
|
*
|
||||||||
|
101.SCH
|
XBRL Taxonomy Extension Schema Document
|
*
|
||||||||
|
101.CAL
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
*
|
||||||||
|
101.DEF
|
XBRL Taxonomy Extension Definition Linkbase Document
|
*
|
||||||||
|
101.LAB
|
XBRL Taxonomy Extension Label Linkbase Document
|
*
|
||||||||
|
101.PRE
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
*
|
||||||||
52
TABLE OF CONTENTS
Part I Financial InformationItem 1 Financial StatementsNote 1. Summary Of Significant Accounting PoliciesNote 2. Marketable Securities and Fair Value MeasurementsNote 3. Balance Sheet ComponentsNote 4. Goodwill and Long-lived AssetsNote 5. Credit FacilitiesNote 6. Legal ProceedingsNote 7. Commitments and ContingenciesNote 8. Stock-based CompensationNote 9. Common Stock Repurchase ProgramNote 10. Accounting For Income TaxesNote 11. Net Income (loss) Per ShareNote 12. Segments and Geographical InformationNote 13. Subsequent EventItem 2. Management S Discussion and Analysis Of Financial Condition and Results Of OperationsItem 3. Quantitative and Qualitative Disclosures About Market RiskItem 4. Controls and ProceduresPart II Other InformationItem 1. Legal ProceedingsItem 1A. Risk FactorsItem 2. Unregistered Sales Of Equity Securities and Use Of ProceedsItem 3. Defaults Upon Senior SecuritiesItem 4. Mine Safety DisclosuresItem 5. Other InformationItem 6. Exhibits